US20240034761A1 - Regeneration of mammalian tissues using synthetic immodulins - Google Patents
Regeneration of mammalian tissues using synthetic immodulins Download PDFInfo
- Publication number
- US20240034761A1 US20240034761A1 US18/264,233 US202218264233A US2024034761A1 US 20240034761 A1 US20240034761 A1 US 20240034761A1 US 202218264233 A US202218264233 A US 202218264233A US 2024034761 A1 US2024034761 A1 US 2024034761A1
- Authority
- US
- United States
- Prior art keywords
- myeloid
- peptide
- immodulin
- acid
- synthetic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000008929 regeneration Effects 0.000 title claims abstract description 6
- 238000011069 regeneration method Methods 0.000 title claims abstract description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 137
- 210000004027 cell Anatomy 0.000 claims abstract description 62
- 238000000034 method Methods 0.000 claims abstract description 39
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 22
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 claims abstract description 21
- 229940099552 hyaluronan Drugs 0.000 claims abstract description 20
- 239000000203 mixture Substances 0.000 claims abstract description 16
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 claims abstract description 15
- 108010045676 holotransferrin Proteins 0.000 claims abstract description 14
- 102100032855 Sialoadhesin Human genes 0.000 claims abstract description 13
- 238000001727 in vivo Methods 0.000 claims abstract description 13
- 101000868472 Homo sapiens Sialoadhesin Proteins 0.000 claims abstract description 11
- 230000001965 increasing effect Effects 0.000 claims abstract description 8
- 101150035137 Clec9a gene Proteins 0.000 claims abstract description 6
- 230000001114 myogenic effect Effects 0.000 claims abstract description 5
- 230000004069 differentiation Effects 0.000 claims description 43
- 239000003550 marker Substances 0.000 claims description 32
- -1 calcified deposits Proteins 0.000 claims description 31
- 210000004962 mammalian cell Anatomy 0.000 claims description 31
- 150000001413 amino acids Chemical class 0.000 claims description 20
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 claims description 10
- 210000001519 tissue Anatomy 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 8
- 229960002938 bexarotene Drugs 0.000 claims description 8
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims description 7
- 101100496087 Mus musculus Clec12a gene Proteins 0.000 claims description 7
- 230000004936 stimulating effect Effects 0.000 claims description 7
- MUFJHYRCIHHATF-UHFFFAOYSA-N 2-(3-phenyl-4,5-dihydro-1,2-oxazol-5-yl)acetic acid Chemical compound O1C(CC(=O)O)CC(C=2C=CC=CC=2)=N1 MUFJHYRCIHHATF-UHFFFAOYSA-N 0.000 claims description 6
- KPSRODZRAIWAKH-JTQLQIEISA-N Ciprofibrate Natural products C1=CC(OC(C)(C)C(O)=O)=CC=C1[C@H]1C(Cl)(Cl)C1 KPSRODZRAIWAKH-JTQLQIEISA-N 0.000 claims description 6
- NAXSRXHZFIBFMI-UHFFFAOYSA-N GW 3965 Chemical compound OC(=O)CC1=CC=CC(OCCCN(CC(C=2C=CC=CC=2)C=2C=CC=CC=2)CC=2C(=C(C=CC=2)C(F)(F)F)Cl)=C1 NAXSRXHZFIBFMI-UHFFFAOYSA-N 0.000 claims description 6
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 6
- 102000003814 Interleukin-10 Human genes 0.000 claims description 6
- 108090000174 Interleukin-10 Proteins 0.000 claims description 6
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 claims description 6
- KPSRODZRAIWAKH-UHFFFAOYSA-N ciprofibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1C1C(Cl)(Cl)C1 KPSRODZRAIWAKH-UHFFFAOYSA-N 0.000 claims description 6
- 229960002174 ciprofibrate Drugs 0.000 claims description 6
- 125000004122 cyclic group Chemical group 0.000 claims description 6
- MQOBSOSZFYZQOK-UHFFFAOYSA-N fenofibric acid Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1C(=O)C1=CC=C(Cl)C=C1 MQOBSOSZFYZQOK-UHFFFAOYSA-N 0.000 claims description 6
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 claims description 6
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 claims description 6
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims description 5
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims description 5
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims description 5
- 229960000701 fenofibric acid Drugs 0.000 claims description 5
- 229960001680 ibuprofen Drugs 0.000 claims description 5
- 229910052751 metal Inorganic materials 0.000 claims description 5
- 239000002184 metal Substances 0.000 claims description 5
- 229960003104 ornithine Drugs 0.000 claims description 5
- WBYWAXJHAXSJNI-VOTSOKGWSA-N trans-cinnamic acid Chemical compound OC(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-N 0.000 claims description 5
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 4
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 claims description 4
- HSTZMXCBWJGKHG-UHFFFAOYSA-N (E)-piceid Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=CC(C=CC=2C=CC(O)=CC=2)=C1 HSTZMXCBWJGKHG-UHFFFAOYSA-N 0.000 claims description 4
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 claims description 4
- GYSCBCSGKXNZRH-UHFFFAOYSA-N 1-benzothiophene-2-carboxamide Chemical compound C1=CC=C2SC(C(=O)N)=CC2=C1 GYSCBCSGKXNZRH-UHFFFAOYSA-N 0.000 claims description 4
- JWHYSEDOYMYMNM-QGZVFWFLSA-N 2-[4-[(2r)-2-ethoxy-3-[4-(trifluoromethyl)phenoxy]propyl]sulfanyl-2-methylphenoxy]acetic acid Chemical compound C([C@@H](OCC)CSC=1C=C(C)C(OCC(O)=O)=CC=1)OC1=CC=C(C(F)(F)F)C=C1 JWHYSEDOYMYMNM-QGZVFWFLSA-N 0.000 claims description 4
- ILUPZUOBHCUBKB-UHFFFAOYSA-N 2-methyl-2-(4-{[({4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl}carbonyl)amino]methyl}phenoxy)propanoic acid Chemical compound CC=1N=C(C=2C=CC(=CC=2)C(F)(F)F)SC=1C(=O)NCC1=CC=C(OC(C)(C)C(O)=O)C=C1 ILUPZUOBHCUBKB-UHFFFAOYSA-N 0.000 claims description 4
- DUQSBRQHALCSLC-UHFFFAOYSA-N 2-prop-2-ynyloctanoic acid Chemical compound CCCCCCC(C(O)=O)CC#C DUQSBRQHALCSLC-UHFFFAOYSA-N 0.000 claims description 4
- WGLMBRZXZDAQHP-UHFFFAOYSA-N BMS 195614 Chemical compound C=1C=C2C(C)(C)CC=C(C=3C=C4C=CC=CC4=NC=3)C2=CC=1C(=O)NC1=CC=C(C(O)=O)C=C1 WGLMBRZXZDAQHP-UHFFFAOYSA-N 0.000 claims description 4
- VUODRPPTYLBGFM-CMDGGOBGSA-N BMS-453 Chemical compound C12=CC(\C=C\C=3C=CC(=CC=3)C(O)=O)=CC=C2C(C)(C)CC=C1C1=CC=CC=C1 VUODRPPTYLBGFM-CMDGGOBGSA-N 0.000 claims description 4
- 101150000943 Clec10a gene Proteins 0.000 claims description 4
- 102000004420 Creatine Kinase Human genes 0.000 claims description 4
- 108010042126 Creatine kinase Proteins 0.000 claims description 4
- GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Natural products CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 claims description 4
- HWVNEWGKWRGSRK-UHFFFAOYSA-N GW 0742 Chemical compound CC=1N=C(C=2C=C(F)C(=CC=2)C(F)(F)F)SC=1CSC1=CC=C(OCC(O)=O)C(C)=C1 HWVNEWGKWRGSRK-UHFFFAOYSA-N 0.000 claims description 4
- BYTNEISLBIENSA-MDZDMXLPSA-N GW 4064 Chemical compound CC(C)C=1ON=C(C=2C(=CC=CC=2Cl)Cl)C=1COC(C=C1Cl)=CC=C1\C=C\C1=CC=CC(C(O)=O)=C1 BYTNEISLBIENSA-MDZDMXLPSA-N 0.000 claims description 4
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 claims description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 4
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 4
- 235000021353 Lignoceric acid Nutrition 0.000 claims description 4
- CQXMAMUUWHYSIY-UHFFFAOYSA-N Lignoceric acid Natural products CCCCCCCCCCCCCCCCCCCCCCCC(=O)OCCC1=CC=C(O)C=C1 CQXMAMUUWHYSIY-UHFFFAOYSA-N 0.000 claims description 4
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims description 4
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims description 4
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 4
- LZCDAPDGXCYOEH-UHFFFAOYSA-N adapalene Chemical compound C1=C(C(O)=O)C=CC2=CC(C3=CC=C(C(=C3)C34CC5CC(CC(C5)C3)C4)OC)=CC=C21 LZCDAPDGXCYOEH-UHFFFAOYSA-N 0.000 claims description 4
- 229960002916 adapalene Drugs 0.000 claims description 4
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 4
- 229930010822 amorfrutin 4 Natural products 0.000 claims description 4
- UAMAHWUELDAAIA-LDADJPATSA-N amorfrutin 4 Chemical compound OC(=O)C1=C(O)C(C/C=C(C)/CCC=C(C)C)=C(O)C=C1CCC1=CC=CC=C1 UAMAHWUELDAAIA-LDADJPATSA-N 0.000 claims description 4
- BGYWMHFOMULQIA-UHFFFAOYSA-N amorfrutin B Natural products COc1cc(CCc2ccccc2)c(C(O)=O)c(O)c1CCC(C)CCC=C(C)C BGYWMHFOMULQIA-UHFFFAOYSA-N 0.000 claims description 4
- FOIVPCKZDPCJJY-JQIJEIRASA-N arotinoid acid Chemical compound C=1C=C(C(CCC2(C)C)(C)C)C2=CC=1C(/C)=C/C1=CC=C(C(O)=O)C=C1 FOIVPCKZDPCJJY-JQIJEIRASA-N 0.000 claims description 4
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims description 4
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims description 4
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims description 4
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims description 4
- FARYTWBWLZAXNK-WAYWQWQTSA-N ethyl (z)-3-(methylamino)but-2-enoate Chemical compound CCOC(=O)\C=C(\C)NC FARYTWBWLZAXNK-WAYWQWQTSA-N 0.000 claims description 4
- 229960003627 gemfibrozil Drugs 0.000 claims description 4
- 229960003764 polydatin Drugs 0.000 claims description 4
- 235000021283 resveratrol Nutrition 0.000 claims description 4
- 229940016667 resveratrol Drugs 0.000 claims description 4
- HSTZMXCBWJGKHG-CUYWLFDKSA-N trans-piceid Polymers O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(\C=C\C=2C=CC(O)=CC=2)=C1 HSTZMXCBWJGKHG-CUYWLFDKSA-N 0.000 claims description 4
- 229940074410 trehalose Drugs 0.000 claims description 4
- 229940096998 ursolic acid Drugs 0.000 claims description 4
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 claims description 4
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 claims description 4
- 229960000604 valproic acid Drugs 0.000 claims description 4
- KZSKGLFYQAYZCO-UHFFFAOYSA-N 2-[3-[2-chloro-4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]phenyl]-3-hydroxyazetidin-1-yl]pyridine-4-carboxylic acid Chemical compound OC(=O)C1=CC=NC(N2CC(O)(C2)C=2C(=CC(OCC=3C(=NOC=3C3CC3)C=3C(=CC=CC=3Cl)Cl)=CC=2)Cl)=C1 KZSKGLFYQAYZCO-UHFFFAOYSA-N 0.000 claims description 3
- FHQXLWCFSUSXBF-UHFFFAOYSA-N 6-chloro-5-[4-(1-hydroxycyclobutyl)phenyl]-1h-indole-3-carboxylic acid Chemical compound C1=C2C(C(=O)O)=CNC2=CC(Cl)=C1C(C=C1)=CC=C1C1(O)CCC1 FHQXLWCFSUSXBF-UHFFFAOYSA-N 0.000 claims description 3
- RTRQQBHATOEIAF-UHFFFAOYSA-N AICA riboside Natural products NC1=C(C(=O)N)N=CN1C1C(O)C(O)C(CO)O1 RTRQQBHATOEIAF-UHFFFAOYSA-N 0.000 claims description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims description 3
- 229920000858 Cyclodextrin Polymers 0.000 claims description 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 3
- 102100032970 Myogenin Human genes 0.000 claims description 3
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims description 3
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 claims description 3
- RTRQQBHATOEIAF-UUOKFMHZSA-N acadesine Chemical compound NC1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 RTRQQBHATOEIAF-UUOKFMHZSA-N 0.000 claims description 3
- FIHJKUPKCHIPAT-AHIGJZGOSA-N artesunate Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@@H](OC(=O)CCC(O)=O)[C@@H]4C FIHJKUPKCHIPAT-AHIGJZGOSA-N 0.000 claims description 3
- 229960004991 artesunate Drugs 0.000 claims description 3
- 239000003833 bile salt Substances 0.000 claims description 3
- 229940070042 cilofexor Drugs 0.000 claims description 3
- 229940003092 decanoic acid Drugs 0.000 claims description 3
- 229960000556 fingolimod Drugs 0.000 claims description 3
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 claims description 3
- 210000004698 lymphocyte Anatomy 0.000 claims description 3
- 230000000527 lymphocytic effect Effects 0.000 claims description 3
- 230000002188 osteogenic effect Effects 0.000 claims description 3
- 229960005095 pioglitazone Drugs 0.000 claims description 3
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 3
- 230000022379 skeletal muscle tissue development Effects 0.000 claims description 3
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 claims description 2
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 claims description 2
- 108700019745 Disks Large Homolog 4 Proteins 0.000 claims description 2
- 102000047174 Disks Large Homolog 4 Human genes 0.000 claims description 2
- 102100038380 Myogenic factor 5 Human genes 0.000 claims description 2
- 108010056785 Myogenin Proteins 0.000 claims description 2
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 claims description 2
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 claims description 2
- 101100025373 Notophthalmus viridescens MYF-5 gene Proteins 0.000 claims description 2
- 102000004067 Osteocalcin Human genes 0.000 claims description 2
- 108090000573 Osteocalcin Proteins 0.000 claims description 2
- 102000004874 Synaptophysin Human genes 0.000 claims description 2
- 108090001076 Synaptophysin Proteins 0.000 claims description 2
- 102100035604 Synaptopodin Human genes 0.000 claims description 2
- 101710119889 Synaptopodin Proteins 0.000 claims description 2
- 102000013127 Vimentin Human genes 0.000 claims description 2
- 108010065472 Vimentin Proteins 0.000 claims description 2
- 102000034337 acetylcholine receptors Human genes 0.000 claims description 2
- 108020000715 acetylcholine receptors Proteins 0.000 claims description 2
- 101150069842 dlg4 gene Proteins 0.000 claims description 2
- 230000002500 effect on skin Effects 0.000 claims description 2
- 230000003328 fibroblastic effect Effects 0.000 claims description 2
- 229940001447 lactate Drugs 0.000 claims description 2
- 230000004766 neurogenesis Effects 0.000 claims description 2
- 230000001272 neurogenic effect Effects 0.000 claims description 2
- 230000011164 ossification Effects 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims description 2
- 210000005048 vimentin Anatomy 0.000 claims description 2
- 230000035755 proliferation Effects 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 54
- 230000024245 cell differentiation Effects 0.000 abstract description 11
- 229920002683 Glycosaminoglycan Polymers 0.000 abstract description 7
- 230000001413 cellular effect Effects 0.000 abstract description 7
- 239000002243 precursor Substances 0.000 abstract description 7
- 230000004071 biological effect Effects 0.000 abstract description 6
- 210000002540 macrophage Anatomy 0.000 abstract description 5
- 210000001616 monocyte Anatomy 0.000 abstract description 5
- 230000017423 tissue regeneration Effects 0.000 abstract description 5
- 230000008685 targeting Effects 0.000 abstract description 3
- 230000014102 antigen processing and presentation of exogenous peptide antigen via MHC class I Effects 0.000 abstract 1
- 230000005784 autoimmunity Effects 0.000 abstract 1
- 238000010668 complexation reaction Methods 0.000 abstract 1
- 230000007850 degeneration Effects 0.000 abstract 1
- 108010038912 Retinoid X Receptors Proteins 0.000 description 31
- 102000034527 Retinoid X Receptors Human genes 0.000 description 31
- 108091008638 NR4A Proteins 0.000 description 19
- 239000000872 buffer Substances 0.000 description 19
- 102000028416 insulin-like growth factor binding Human genes 0.000 description 19
- 108091022911 insulin-like growth factor binding Proteins 0.000 description 19
- 239000003446 ligand Substances 0.000 description 19
- 108090000623 proteins and genes Proteins 0.000 description 19
- 235000018102 proteins Nutrition 0.000 description 16
- 102000004169 proteins and genes Human genes 0.000 description 16
- 102100022679 Nuclear receptor subfamily 4 group A member 1 Human genes 0.000 description 13
- CNWINRVXAYPOMW-FCNJXWMTSA-N 1-stearoyl-2-arachidonoyl-sn-glycero-3-phospho-1D-myo-inositol 4,5-biphosphate Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCC)COP(O)(=O)O[C@@H]1[C@H](O)[C@H](O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H]1O CNWINRVXAYPOMW-FCNJXWMTSA-N 0.000 description 11
- 229940024606 amino acid Drugs 0.000 description 11
- 235000001014 amino acid Nutrition 0.000 description 11
- 150000003384 small molecules Chemical class 0.000 description 11
- 238000003556 assay Methods 0.000 description 10
- 238000001403 relative X-ray reflectometry Methods 0.000 description 10
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 102000006255 nuclear receptors Human genes 0.000 description 9
- 108020004017 nuclear receptors Proteins 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 101100405118 Mus musculus Nr4a1 gene Proteins 0.000 description 8
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 8
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 8
- 101100405120 Xenopus laevis nr4a1 gene Proteins 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- UVVWQQKSNZLUQA-UHFFFAOYSA-N 2-[3,5-dihydroxy-2-(1-oxooctyl)phenyl]acetic acid ethyl ester Chemical compound CCCCCCCC(=O)C1=C(O)C=C(O)C=C1CC(=O)OCC UVVWQQKSNZLUQA-UHFFFAOYSA-N 0.000 description 7
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 7
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 102000013275 Somatomedins Human genes 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 235000014113 dietary fatty acids Nutrition 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 229930195729 fatty acid Natural products 0.000 description 7
- 239000000194 fatty acid Substances 0.000 description 7
- 150000004665 fatty acids Chemical class 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 102100032912 CD44 antigen Human genes 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 238000007918 intramuscular administration Methods 0.000 description 6
- 238000007920 subcutaneous administration Methods 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- 102100033601 Collagen alpha-1(I) chain Human genes 0.000 description 5
- 101001109700 Homo sapiens Nuclear receptor subfamily 4 group A member 1 Proteins 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 102000004311 liver X receptors Human genes 0.000 description 5
- 108090000865 liver X receptors Proteins 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 150000007965 phenolic acids Chemical class 0.000 description 5
- 239000011347 resin Substances 0.000 description 5
- 229920005989 resin Polymers 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- LTLRXTDMXOFBDW-UHFFFAOYSA-N 3-[(4-chlorophenyl)-(1h-indol-3-yl)methyl]-1h-indole Chemical compound C1=CC(Cl)=CC=C1C(C=1C2=CC=CC=C2NC=1)C1=CNC2=CC=CC=C12 LTLRXTDMXOFBDW-UHFFFAOYSA-N 0.000 description 4
- SXKPGYKPQPYJER-UHFFFAOYSA-N 4-(5,7,7,10,10-pentamethyl-2-nitro-8,9-dihydronaphtho[2,3-b][1,5]benzodiazepin-12-yl)benzoic acid Chemical compound C12=CC(C(CCC3(C)C)(C)C)=C3C=C2N(C)C2=CC=C([N+]([O-])=O)C=C2N=C1C1=CC=C(C(O)=O)C=C1 SXKPGYKPQPYJER-UHFFFAOYSA-N 0.000 description 4
- DLFBCHSYAZBTSS-UHFFFAOYSA-N 4-(5,7,7,10,10-pentamethyl-8,9-dihydronaphtho[2,3-b][1,5]benzodiazepin-12-yl)benzoic acid Chemical compound C12=CC(C(CCC3(C)C)(C)C)=C3C=C2N(C)C2=CC=CC=C2N=C1C1=CC=C(C(O)=O)C=C1 DLFBCHSYAZBTSS-UHFFFAOYSA-N 0.000 description 4
- QCPDFNWJBQMXLI-UHFFFAOYSA-N 4-[bis(1h-indol-3-yl)methyl]phenol Chemical compound C1=CC(O)=CC=C1C(C=1C2=CC=CC=C2NC=1)C1=CNC2=CC=CC=C12 QCPDFNWJBQMXLI-UHFFFAOYSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 102000004374 Insulin-like growth factor binding protein 3 Human genes 0.000 description 4
- 108090000965 Insulin-like growth factor binding protein 3 Proteins 0.000 description 4
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
- 101100396933 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) imm2 gene Proteins 0.000 description 4
- 101710196623 Stimulator of interferon genes protein Proteins 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- 108010029483 alpha 1 Chain Collagen Type I Proteins 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- RRGUKTPIGVIEKM-UHFFFAOYSA-N cilostazol Chemical compound C=1C=C2NC(=O)CCC2=CC=1OCCCCC1=NN=NN1C1CCCCC1 RRGUKTPIGVIEKM-UHFFFAOYSA-N 0.000 description 4
- 230000002121 endocytic effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 4
- 229920000669 heparin Polymers 0.000 description 4
- 229960002897 heparin Drugs 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 238000007912 intraperitoneal administration Methods 0.000 description 4
- 210000000066 myeloid cell Anatomy 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- 102000003702 retinoic acid receptors Human genes 0.000 description 4
- 108090000064 retinoic acid receptors Proteins 0.000 description 4
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 102000004217 thyroid hormone receptors Human genes 0.000 description 4
- 108090000721 thyroid hormone receptors Proteins 0.000 description 4
- 230000002103 transcriptional effect Effects 0.000 description 4
- 238000011277 treatment modality Methods 0.000 description 4
- NAGKYJATVFXZKN-UHFFFAOYSA-N 4-[(2-chloro-6-fluorophenyl)methyl]-n-(furan-2-ylmethyl)-3-oxo-1,4-benzothiazine-6-carboxamide Chemical compound FC1=CC=CC(Cl)=C1CN1C2=CC(C(=O)NCC=3OC=CC=3)=CC=C2SCC1=O NAGKYJATVFXZKN-UHFFFAOYSA-N 0.000 description 3
- ZZUKALQMHNSWTK-UHFFFAOYSA-N 4-[2-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)-1,3-dioxolan-2-yl]benzoic acid Chemical compound C=1C=C2C(C)(C)CCC(C)(C)C2=CC=1C1(C=2C=CC(=CC=2)C(O)=O)OCCO1 ZZUKALQMHNSWTK-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 3
- 102100038495 Bile acid receptor Human genes 0.000 description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 3
- PHEDXBVPIONUQT-UHFFFAOYSA-N Cocarcinogen A1 Natural products CCCCCCCCCCCCCC(=O)OC1C(C)C2(O)C3C=C(C)C(=O)C3(O)CC(CO)=CC2C2C1(OC(C)=O)C2(C)C PHEDXBVPIONUQT-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 3
- 102100035857 Glutamate decarboxylase 2 Human genes 0.000 description 3
- 101000603876 Homo sapiens Bile acid receptor Proteins 0.000 description 3
- 101000873786 Homo sapiens Glutamate decarboxylase 2 Proteins 0.000 description 3
- 101001093899 Homo sapiens Retinoic acid receptor RXR-alpha Proteins 0.000 description 3
- 101000640876 Homo sapiens Retinoic acid receptor RXR-beta Proteins 0.000 description 3
- 101000640882 Homo sapiens Retinoic acid receptor RXR-gamma Proteins 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- 108010035210 Iron-Binding Proteins Proteins 0.000 description 3
- 102000008133 Iron-Binding Proteins Human genes 0.000 description 3
- 101100396930 Pseudomonas aeruginosa imm1 gene Proteins 0.000 description 3
- 102100035178 Retinoic acid receptor RXR-alpha Human genes 0.000 description 3
- 102100034253 Retinoic acid receptor RXR-beta Human genes 0.000 description 3
- 102100034262 Retinoic acid receptor RXR-gamma Human genes 0.000 description 3
- 108090000901 Transferrin Proteins 0.000 description 3
- 102000004338 Transferrin Human genes 0.000 description 3
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 3
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 3
- 150000004056 anthraquinones Chemical class 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 229960004588 cilostazol Drugs 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 208000026278 immune system disease Diseases 0.000 description 3
- 238000001361 intraarterial administration Methods 0.000 description 3
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 3
- 230000004770 neurodegeneration Effects 0.000 description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 3
- 150000003907 phosphatidylinositol monophosphates Chemical class 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 229960002256 spironolactone Drugs 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 230000030968 tissue homeostasis Effects 0.000 description 3
- 239000012581 transferrin Substances 0.000 description 3
- 102000009310 vitamin D receptors Human genes 0.000 description 3
- 108050000156 vitamin D receptors Proteins 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- PLQMEXSCSAIXGB-SAXRGWBVSA-N (+)-artemisinic acid Chemical compound C1=C(C)CC[C@H]2[C@H](C)CC[C@@H](C(=C)C(O)=O)[C@H]21 PLQMEXSCSAIXGB-SAXRGWBVSA-N 0.000 description 2
- HPTXLHAHLXOAKV-INIZCTEOSA-N (2S)-2-(1,3-dioxo-2-isoindolyl)-3-(1H-indol-3-yl)propanoic acid Chemical compound O=C1C2=CC=CC=C2C(=O)N1[C@H](C(=O)O)CC1=CNC2=CC=CC=C12 HPTXLHAHLXOAKV-INIZCTEOSA-N 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 2
- CZKBLHCEDVWPRN-JXMROGBWSA-N (3e)-1-methyl-3-(2-oxopropylidene)indol-2-one Chemical compound C1=CC=C2N(C)C(=O)\C(=C\C(C)=O)C2=C1 CZKBLHCEDVWPRN-JXMROGBWSA-N 0.000 description 2
- CDSMSBUVCWHORP-MRVPVSSYSA-N (4s)-4-prop-1-en-2-ylcyclohexene-1-carboxylic acid Chemical compound CC(=C)[C@H]1CCC(C(O)=O)=CC1 CDSMSBUVCWHORP-MRVPVSSYSA-N 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- XRILCFTWUCUKJR-INFSMZHSSA-N 2'-3'-cGAMP Chemical compound C([C@H]([C@H]1O)O2)OP(O)(=O)O[C@H]3[C@@H](O)[C@H](N4C5=NC=NC(N)=C5N=C4)O[C@@H]3COP(O)(=O)O[C@H]1[C@@H]2N1C=NC2=C1NC(N)=NC2=O XRILCFTWUCUKJR-INFSMZHSSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- APCLRHPWFCQIMG-UHFFFAOYSA-N 4-(5,6-dimethoxy-1-benzothiophen-2-yl)-4-oxobutanoic acid Chemical compound C1=C(OC)C(OC)=CC2=C1SC(C(=O)CCC(O)=O)=C2 APCLRHPWFCQIMG-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- 208000009304 Acute Kidney Injury Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102100036845 C-C motif chemokine 22 Human genes 0.000 description 2
- 150000008574 D-amino acids Chemical class 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- DHCLVCXQIBBOPH-UHFFFAOYSA-N Glycerol 2-phosphate Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 2
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 2
- 102000004371 Insulin-like growth factor binding protein 5 Human genes 0.000 description 2
- 108090000961 Insulin-like growth factor binding protein 5 Proteins 0.000 description 2
- QURCVMIEKCOAJU-HWKANZROSA-N Isoferulic acid Natural products COC1=CC=C(\C=C\C(O)=O)C=C1O QURCVMIEKCOAJU-HWKANZROSA-N 0.000 description 2
- 239000005639 Lauric acid Substances 0.000 description 2
- WNGSUWLDMZFYNZ-UHFFFAOYSA-N Leonurine Chemical compound COC1=CC(C(=O)OCCCCN=C(N)N)=CC(OC)=C1O WNGSUWLDMZFYNZ-UHFFFAOYSA-N 0.000 description 2
- 208000019693 Lung disease Diseases 0.000 description 2
- 229940125791 MSA-2 Drugs 0.000 description 2
- QTDMGAWIBXJNRR-UHFFFAOYSA-N Mangostin Natural products CC(=CCc1c(O)cc2Oc3cc(C)c(O)c(CC=C(C)C)c3C(=O)c2c1O)C QTDMGAWIBXJNRR-UHFFFAOYSA-N 0.000 description 2
- 101710162106 Merozoite surface antigen 2 Proteins 0.000 description 2
- 101150026563 NR4A2 gene Proteins 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 102100030090 Probable ATP-dependent RNA helicase DHX58 Human genes 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 229940044606 RIG-I agonist Drugs 0.000 description 2
- 108091005685 RIG-I-like receptors Proteins 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 208000033626 Renal failure acute Diseases 0.000 description 2
- 108010029176 Sialic Acid Binding Ig-like Lectin 1 Proteins 0.000 description 2
- 102100035533 Stimulator of interferon genes protein Human genes 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 201000011040 acute kidney failure Diseases 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- GNRIZKKCNOBBMO-UHFFFAOYSA-N alpha-mangostin Chemical compound OC1=C(CC=C(C)C)C(O)=C2C(=O)C3=C(CC=C(C)C)C(OC)=C(O)C=C3OC2=C1 GNRIZKKCNOBBMO-UHFFFAOYSA-N 0.000 description 2
- ZVFQDLCERPGZMO-UHFFFAOYSA-N alpha-mangostin Natural products OC1=C(CC=C(C)C)C(O)=C2C(=O)C3=C(CC=C(C)C)C(OC)=C(O)C=C3CC2=C1 ZVFQDLCERPGZMO-UHFFFAOYSA-N 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- QGJZLNKBHJESQX-FZFNOLFKSA-N betulinic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 description 2
- PKFDLKSEZWEFGL-MHARETSRSA-N c-di-GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]3[C@@H](O)[C@H](N4C5=C(C(NC(N)=N5)=O)N=C4)O[C@@H]3COP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 PKFDLKSEZWEFGL-MHARETSRSA-N 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- JEJFTTRHGBKKEI-OKILXGFUSA-N deoxyschizandrin Chemical compound C1[C@H](C)[C@H](C)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC JEJFTTRHGBKKEI-OKILXGFUSA-N 0.000 description 2
- DKYWVDODHFEZIM-NSHDSACASA-N dexketoprofen Chemical compound OC(=O)[C@@H](C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-NSHDSACASA-N 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 229960003878 haloperidol Drugs 0.000 description 2
- 229940014041 hyaluronate Drugs 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 239000002523 lectin Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- ODSAJRWPLSVEHJ-UHFFFAOYSA-M lithium 4,5-difluoro-2-[(6-imidazol-1-ylpyridazine-3-carbonyl)amino]benzoate Chemical compound N1(C=NC=C1)C1=CC=C(N=N1)C(=O)NC1=C(C(=O)[O-])C=C(C(=C1)F)F.[Li+] ODSAJRWPLSVEHJ-UHFFFAOYSA-M 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- FBSFWRHWHYMIOG-UHFFFAOYSA-N methyl 3,4,5-trihydroxybenzoate Chemical compound COC(=O)C1=CC(O)=C(O)C(O)=C1 FBSFWRHWHYMIOG-UHFFFAOYSA-N 0.000 description 2
- 210000003098 myoblast Anatomy 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 230000012223 nuclear import Effects 0.000 description 2
- 230000025308 nuclear transport Effects 0.000 description 2
- 210000000963 osteoblast Anatomy 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 235000017807 phytochemicals Nutrition 0.000 description 2
- 229930000223 plant secondary metabolite Natural products 0.000 description 2
- VCMMXZQDRFWYSE-UHFFFAOYSA-N plumbagin Chemical compound C1=CC=C2C(=O)C(C)=CC(=O)C2=C1O VCMMXZQDRFWYSE-UHFFFAOYSA-N 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000000528 statistical test Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000000472 traumatic effect Effects 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- WJHZBTMHUNVIKC-UHFFFAOYSA-N valerylsalicylic acid Chemical compound CCCCC(=O)OC1=CC=CC=C1C(O)=O WJHZBTMHUNVIKC-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- JNELGWHKGNBSMD-UHFFFAOYSA-N xanthone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3OC2=C1 JNELGWHKGNBSMD-UHFFFAOYSA-N 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 1
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- QBLFZIBJXUQVRF-UHFFFAOYSA-N (4-bromophenyl)boronic acid Chemical compound OB(O)C1=CC=C(Br)C=C1 QBLFZIBJXUQVRF-UHFFFAOYSA-N 0.000 description 1
- UUTKICFRNVKFRG-WDSKDSINSA-N (4R)-3-[oxo-[(2S)-5-oxo-2-pyrrolidinyl]methyl]-4-thiazolidinecarboxylic acid Chemical compound OC(=O)[C@@H]1CSCN1C(=O)[C@H]1NC(=O)CC1 UUTKICFRNVKFRG-WDSKDSINSA-N 0.000 description 1
- KQJSQWZMSAGSHN-UHFFFAOYSA-N (9beta,13alpha,14beta,20alpha)-3-hydroxy-9,13-dimethyl-2-oxo-24,25,26-trinoroleana-1(10),3,5,7-tetraen-29-oic acid Natural products CC12CCC3(C)C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C2=CC=C2C1=CC(=O)C(O)=C2C KQJSQWZMSAGSHN-UHFFFAOYSA-N 0.000 description 1
- QHBZHVUGQROELI-SOFGYWHQSA-N (E)-10-hydroxydec-2-enoic acid Chemical compound OCCCCCCC\C=C\C(O)=O QHBZHVUGQROELI-SOFGYWHQSA-N 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- HKWJHKSHEWVOSS-MRQSADPDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phospho-(1D-myo-inositol-4,5-bisphosphate) Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)O[C@@H]1[C@H](O)[C@H](O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H]1O HKWJHKSHEWVOSS-MRQSADPDSA-N 0.000 description 1
- ICZSAXDKFXTSGL-UHFFFAOYSA-N 1-[4-[5-carbamoyl-2-[(2-ethyl-5-methylpyrazole-3-carbonyl)amino]benzimidazol-1-yl]butyl]-2-[(2-ethyl-5-methylpyrazole-3-carbonyl)amino]benzimidazole-5-carboxamide Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC=C2N1CCCCN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC=C12)C(N)=O)C(N)=O ICZSAXDKFXTSGL-UHFFFAOYSA-N 0.000 description 1
- QOPBEBWGSGFROG-UHFFFAOYSA-N 2-(1h-indol-2-yl)acetic acid Chemical class C1=CC=C2NC(CC(=O)O)=CC2=C1 QOPBEBWGSGFROG-UHFFFAOYSA-N 0.000 description 1
- PXEZTIWVRVSYOK-UHFFFAOYSA-N 2-(3,6-diacetyloxy-2,7-dichloro-9h-xanthen-9-yl)benzoic acid Chemical compound C1=2C=C(Cl)C(OC(=O)C)=CC=2OC2=CC(OC(C)=O)=C(Cl)C=C2C1C1=CC=CC=C1C(O)=O PXEZTIWVRVSYOK-UHFFFAOYSA-N 0.000 description 1
- 239000003315 2-(4-chlorophenoxy)-2-methylpropanoic acid Substances 0.000 description 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
- KUPHXIFBKAORGY-UHFFFAOYSA-N 2-amino-3-iodo-4-methylbenzoic acid Chemical compound CC1=CC=C(C(O)=O)C(N)=C1I KUPHXIFBKAORGY-UHFFFAOYSA-N 0.000 description 1
- QSTURKXDYNIRGT-UHFFFAOYSA-N 2-hydroxydec-2-enoic acid Chemical compound CCCCCCCC=C(O)C(O)=O QSTURKXDYNIRGT-UHFFFAOYSA-N 0.000 description 1
- KDWPJVXNULWVPC-UHFFFAOYSA-N 2-prop-1-ynyloctanoic acid Chemical compound CCCCCCC(C(O)=O)C#CC KDWPJVXNULWVPC-UHFFFAOYSA-N 0.000 description 1
- QGJZLNKBHJESQX-UHFFFAOYSA-N 3-Epi-Betulin-Saeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CCC3C21C QGJZLNKBHJESQX-UHFFFAOYSA-N 0.000 description 1
- KIWODJBCHRADND-UHFFFAOYSA-N 3-anilino-4-[1-[3-(1-imidazolyl)propyl]-3-indolyl]pyrrole-2,5-dione Chemical compound O=C1NC(=O)C(C=2C3=CC=CC=C3N(CCCN3C=NC=C3)C=2)=C1NC1=CC=CC=C1 KIWODJBCHRADND-UHFFFAOYSA-N 0.000 description 1
- PRRZDZJYSJLDBS-UHFFFAOYSA-N 3-bromo-2-oxopropanoic acid Chemical compound OC(=O)C(=O)CBr PRRZDZJYSJLDBS-UHFFFAOYSA-N 0.000 description 1
- CLOUCVRNYSHRCF-UHFFFAOYSA-N 3beta-Hydroxy-20(29)-Lupen-3,27-oic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C(O)=O)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C CLOUCVRNYSHRCF-UHFFFAOYSA-N 0.000 description 1
- TYNLGDBUJLVSMA-UHFFFAOYSA-N 4,5-diacetyloxy-9,10-dioxo-2-anthracenecarboxylic acid Chemical compound O=C1C2=CC(C(O)=O)=CC(OC(C)=O)=C2C(=O)C2=C1C=CC=C2OC(=O)C TYNLGDBUJLVSMA-UHFFFAOYSA-N 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- UILNVCFXMNSVLA-UHFFFAOYSA-N 4-fluoro-n-(3-fluoro-4-methylphenyl)-3-[(4-methoxyphenyl)methylsulfamoyl]benzamide Chemical compound C1=CC(OC)=CC=C1CNS(=O)(=O)C1=CC(C(=O)NC=2C=C(F)C(C)=CC=2)=CC=C1F UILNVCFXMNSVLA-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- QETLKNDKQOXZRP-XTGBIJOFSA-N 5alpha-cholest-8-en-3beta-ol Chemical compound C([C@@]12C)C[C@H](O)C[C@@H]1CCC1=C2CC[C@]2(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]21 QETLKNDKQOXZRP-XTGBIJOFSA-N 0.000 description 1
- QETLKNDKQOXZRP-UHFFFAOYSA-N 5alpha-cholest-8-en-3beta-ol Natural products CC12CCC(O)CC1CCC1=C2CCC2(C)C(C(C)CCCC(C)C)CCC21 QETLKNDKQOXZRP-UHFFFAOYSA-N 0.000 description 1
- YDSHHDISKUSKFW-UHFFFAOYSA-N 7-[(1,3-benzothiazol-2-ylamino)-[4-(difluoromethoxy)phenyl]methyl]quinolin-8-ol Chemical compound C1=CC2=CC=CN=C2C(O)=C1C(NC=1SC2=CC=CC=C2N=1)C1=CC=C(OC(F)F)C=C1 YDSHHDISKUSKFW-UHFFFAOYSA-N 0.000 description 1
- 239000001606 7-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-hydroxyphenyl)chroman-4-one Substances 0.000 description 1
- YSGBFDHVEQJPPX-UHFFFAOYSA-N 7-[[4-(difluoromethoxy)phenyl]-[(5-methoxy-1,3-benzothiazol-2-yl)amino]methyl]quinolin-8-ol Chemical compound COc1ccc2sc(NC(c3ccc(OC(F)F)cc3)c3ccc4cccnc4c3O)nc2c1 YSGBFDHVEQJPPX-UHFFFAOYSA-N 0.000 description 1
- 102100036601 Aggrecan core protein Human genes 0.000 description 1
- 108010067219 Aggrecans Proteins 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 102100023635 Alpha-fetoprotein Human genes 0.000 description 1
- 108010036221 Aquaporin 2 Proteins 0.000 description 1
- 102000011899 Aquaporin 2 Human genes 0.000 description 1
- 102000004392 Aquaporin 5 Human genes 0.000 description 1
- 108090000976 Aquaporin 5 Proteins 0.000 description 1
- 101100297694 Arabidopsis thaliana PIP2-7 gene Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- DIZWSDNSTNAYHK-XGWVBXMLSA-N Betulinic acid Natural products CC(=C)[C@@H]1C[C@H]([C@H]2CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(=O)O DIZWSDNSTNAYHK-XGWVBXMLSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108050002102 C-C motif chemokine 22 Proteins 0.000 description 1
- 108090000342 C-Type Lectins Proteins 0.000 description 1
- 102000003930 C-Type Lectins Human genes 0.000 description 1
- 102100040843 C-type lectin domain family 4 member M Human genes 0.000 description 1
- 101150085274 CLEC4A gene Proteins 0.000 description 1
- 108091011896 CSF1 Proteins 0.000 description 1
- 102100021851 Calbindin Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- AQKDBFWJOPNOKZ-UHFFFAOYSA-N Celastrol Natural products CC12CCC3(C)C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C2=CC=C2C1=CC(=O)C(=O)C2C AQKDBFWJOPNOKZ-UHFFFAOYSA-N 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- 101710090667 Collagen alpha-1(I) chain Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 108010036941 Cyclosporins Proteins 0.000 description 1
- 206010011777 Cystinosis Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- HSNZZMHEPUFJNZ-QMTIVRBISA-N D-keto-manno-heptulose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)C(=O)CO HSNZZMHEPUFJNZ-QMTIVRBISA-N 0.000 description 1
- HAIWUXASLYEWLM-UHFFFAOYSA-N D-manno-Heptulose Natural products OCC1OC(O)(CO)C(O)C(O)C1O HAIWUXASLYEWLM-UHFFFAOYSA-N 0.000 description 1
- UCTLRSWJYQTBFZ-UHFFFAOYSA-N Dehydrocholesterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCCC(C)C)CCC33)C)C3=CC=C21 UCTLRSWJYQTBFZ-UHFFFAOYSA-N 0.000 description 1
- 229920000045 Dermatan sulfate Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 108700041153 Filaggrin Proteins Proteins 0.000 description 1
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 241000709721 Hepatovirus A Species 0.000 description 1
- 108090000353 Histone deacetylase Proteins 0.000 description 1
- 102100038720 Histone deacetylase 9 Human genes 0.000 description 1
- 102100028798 Homeodomain-only protein Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000929940 Homo sapiens Adrenocortical dysplasia protein homolog Proteins 0.000 description 1
- 101000766965 Homo sapiens C-type lectin domain family 4 member K Proteins 0.000 description 1
- 101000749311 Homo sapiens C-type lectin domain family 4 member M Proteins 0.000 description 1
- 101000897416 Homo sapiens CD209 antigen Proteins 0.000 description 1
- 101000898082 Homo sapiens Calbindin Proteins 0.000 description 1
- 101000839095 Homo sapiens Homeodomain-only protein Proteins 0.000 description 1
- 101001018034 Homo sapiens Lymphocyte antigen 75 Proteins 0.000 description 1
- 101000589002 Homo sapiens Myogenin Proteins 0.000 description 1
- 101001109698 Homo sapiens Nuclear receptor subfamily 4 group A member 2 Proteins 0.000 description 1
- 101001109689 Homo sapiens Nuclear receptor subfamily 4 group A member 3 Proteins 0.000 description 1
- 101001100101 Homo sapiens Retinoic acid-induced protein 3 Proteins 0.000 description 1
- 101000643024 Homo sapiens Stimulator of interferon genes protein Proteins 0.000 description 1
- 101000807859 Homo sapiens Vasopressin V2 receptor Proteins 0.000 description 1
- 101000730577 Homo sapiens p21-activated protein kinase-interacting protein 1 Proteins 0.000 description 1
- 108010013214 Hyaluronan Receptors Proteins 0.000 description 1
- 102000018866 Hyaluronan Receptors Human genes 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- HCUARRIEZVDMPT-UHFFFAOYSA-N Indole-2-carboxylic acid Chemical class C1=CC=C2NC(C(=O)O)=CC2=C1 HCUARRIEZVDMPT-UHFFFAOYSA-N 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 102000004375 Insulin-like growth factor-binding protein 1 Human genes 0.000 description 1
- 108090000957 Insulin-like growth factor-binding protein 1 Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- ZMOIGGHUSNHCAB-UHFFFAOYSA-N Isoplumbagin Natural products C1=CC(O)=C2C(=O)C(C)=CC(=O)C2=C1 ZMOIGGHUSNHCAB-UHFFFAOYSA-N 0.000 description 1
- 229920000288 Keratan sulfate Polymers 0.000 description 1
- 102100023970 Keratin, type I cytoskeletal 10 Human genes 0.000 description 1
- 108010065038 Keratin-10 Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- HSNZZMHEPUFJNZ-UHFFFAOYSA-N L-galacto-2-Heptulose Natural products OCC(O)C(O)C(O)C(O)C(=O)CO HSNZZMHEPUFJNZ-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 102100031784 Loricrin Human genes 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 101100096242 Mus musculus Sox9 gene Proteins 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- 101150111110 NKX2-1 gene Proteins 0.000 description 1
- 101150088803 NR4A1 gene Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 102100022676 Nuclear receptor subfamily 4 group A member 2 Human genes 0.000 description 1
- 102100022673 Nuclear receptor subfamily 4 group A member 3 Human genes 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000022873 Ocular disease Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101000971435 Oryctolagus cuniculus Protein kinase C gamma type Proteins 0.000 description 1
- 206010033109 Ototoxicity Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000023984 PPAR alpha Human genes 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- 108010044210 PPAR-beta Proteins 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 208000034038 Pathologic Neovascularization Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000011384 Pendrin Human genes 0.000 description 1
- 108050001616 Pendrin Proteins 0.000 description 1
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 1
- 244000025272 Persea americana Species 0.000 description 1
- 235000008673 Persea americana Nutrition 0.000 description 1
- 108091036414 Polyinosinic:polycytidylic acid Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 102000014458 Protein Kinase C-epsilon Human genes 0.000 description 1
- 108010078137 Protein Kinase C-epsilon Proteins 0.000 description 1
- 102100024923 Protein kinase C beta type Human genes 0.000 description 1
- 101710094033 Protein kinase C beta type Proteins 0.000 description 1
- 229940123924 Protein kinase C inhibitor Drugs 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- CDSMSBUVCWHORP-UHFFFAOYSA-N R-perillic acid Natural products CC(=C)C1CCC(C(O)=O)=CC1 CDSMSBUVCWHORP-UHFFFAOYSA-N 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 101150078416 RXR gene Proteins 0.000 description 1
- 102000005622 Receptor for Advanced Glycation End Products Human genes 0.000 description 1
- 108010045108 Receptor for Advanced Glycation End Products Proteins 0.000 description 1
- 102100038453 Retinoic acid-induced protein 3 Human genes 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 206010039020 Rhabdomyolysis Diseases 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- QHBZHVUGQROELI-UHFFFAOYSA-N Royal Jelly acid Natural products OCCCCCCCC=CC(O)=O QHBZHVUGQROELI-UHFFFAOYSA-N 0.000 description 1
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
- 101100456541 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) MEC3 gene Proteins 0.000 description 1
- 101100483663 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) UFD1 gene Proteins 0.000 description 1
- ILRCGYURZSFMEG-UHFFFAOYSA-N Salidroside Natural products OC1C(O)C(O)C(CO)OC1OCCC1=CC=C(O)C=C1 ILRCGYURZSFMEG-UHFFFAOYSA-N 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- QNAZTOHXCZPOSA-UHFFFAOYSA-N Sobetirome Chemical compound C1=C(O)C(C(C)C)=CC(CC=2C(=CC(OCC(O)=O)=CC=2C)C)=C1 QNAZTOHXCZPOSA-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical class [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108091021474 TMEM173 Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 102000009843 Thyroglobulin Human genes 0.000 description 1
- 108010034949 Thyroglobulin Proteins 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 102000002689 Toll-like receptor Human genes 0.000 description 1
- 108020000411 Toll-like receptor Proteins 0.000 description 1
- 108010015865 Transferrins Proteins 0.000 description 1
- 102000002070 Transferrins Human genes 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 102100037108 Vasopressin V2 receptor Human genes 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- HIMJIPRMECETLJ-UHFFFAOYSA-N Wogonin Natural products COc1cc(O)c(O)c2C(=O)C=C(Oc12)c3ccccc3 HIMJIPRMECETLJ-UHFFFAOYSA-N 0.000 description 1
- KLGQSVMIPOVQAX-UHFFFAOYSA-N XAV939 Chemical compound N=1C=2CCSCC=2C(O)=NC=1C1=CC=C(C(F)(F)F)C=C1 KLGQSVMIPOVQAX-UHFFFAOYSA-N 0.000 description 1
- UJVUMTUBMCYKBK-BNOPZSDTSA-N [(2r)-2-hexadecanoyloxy-3-[hydroxy-[(2r,3r,5s,6r)-2,3,5,6-tetrahydroxy-4-phosphonooxycyclohexyl]oxyphosphoryl]oxypropyl] hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)OC1[C@H](O)[C@H](O)C(OP(O)(O)=O)[C@H](O)[C@H]1O UJVUMTUBMCYKBK-BNOPZSDTSA-N 0.000 description 1
- ZSZXYWFCIKKZBT-ZVDPZPSOSA-N [(2r)-3-[[(2s,3s,5r,6s)-2,6-dihydroxy-3,4,5-triphosphonooxycyclohexyl]oxy-hydroxyphosphoryl]oxy-2-hexadecanoyloxypropyl] hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)OC1[C@H](O)[C@H](OP(O)(O)=O)C(OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H]1O ZSZXYWFCIKKZBT-ZVDPZPSOSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000000240 adjuvant effect Effects 0.000 description 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
- AVJBPWGFOQAPRH-FWMKGIEWSA-N alpha-L-IdopA-(1->3)-beta-D-GalpNAc4S Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS(O)(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C(O)=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-N 0.000 description 1
- 239000002647 aminoglycoside antibiotic agent Substances 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940045985 antineoplastic platinum compound Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000025194 apoptotic cell clearance Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- LZMOBPWDHUQTKL-RWMBFGLXSA-N artemisinic acid Natural products CC1=C[C@@H]2[C@@H](CCC[C@H]2C(=C)C(=O)O)CC1 LZMOBPWDHUQTKL-RWMBFGLXSA-N 0.000 description 1
- PLQMEXSCSAIXGB-UHFFFAOYSA-N artemisininic acid Natural products C1=C(C)CCC2C(C)CCC(C(=C)C(O)=O)C21 PLQMEXSCSAIXGB-UHFFFAOYSA-N 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 1
- 229940093265 berberine Drugs 0.000 description 1
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 1
- ALPCEXCHMFUSAN-UHFFFAOYSA-N beta-Dihydroplumbagin Natural products C1=CC=C2C(=O)C(C)CC(=O)C2=C1O ALPCEXCHMFUSAN-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000002715 bioenergetic effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 150000005693 branched-chain amino acids Chemical class 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 235000020964 calcitriol Nutrition 0.000 description 1
- 239000011612 calcitriol Substances 0.000 description 1
- 229960005084 calcitriol Drugs 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 230000022159 cartilage development Effects 0.000 description 1
- KQJSQWZMSAGSHN-JJWQIEBTSA-N celastrol Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)[C@](C)(C(O)=O)CC[C@]1(C)CC[C@]2(C)C4=CC=C1C3=CC(=O)C(O)=C1C KQJSQWZMSAGSHN-JJWQIEBTSA-N 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000012054 celltiter-glo Methods 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 230000002648 chondrogenic effect Effects 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N cinnamic acid group Chemical class C(C=CC1=CC=CC=C1)(=O)O WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 229960002842 clobetasol Drugs 0.000 description 1
- 229950008441 clofibric acid Drugs 0.000 description 1
- TXCGAZHTZHNUAI-UHFFFAOYSA-N clofibric acid Chemical compound OC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 TXCGAZHTZHNUAI-UHFFFAOYSA-N 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- JEJFTTRHGBKKEI-UHFFFAOYSA-N deoxyschizandrin Natural products C1C(C)C(C)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC JEJFTTRHGBKKEI-UHFFFAOYSA-N 0.000 description 1
- 229940051593 dermatan sulfate Drugs 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 229960002783 dexketoprofen Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229960004590 diacerein Drugs 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 229960004132 diethyl ether Drugs 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- PZXJOHSZQAEJFE-UHFFFAOYSA-N dihydrobetulinic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(C)C)C5C4CCC3C21C PZXJOHSZQAEJFE-UHFFFAOYSA-N 0.000 description 1
- HESHRHUZIWVEAJ-JGRZULCMSA-N dihydroergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2[C@@H](C3=CC=CC4=NC=C([C]34)C2)C1)C)C1=CC=CC=C1 HESHRHUZIWVEAJ-JGRZULCMSA-N 0.000 description 1
- 229960004704 dihydroergotamine Drugs 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 229940030275 epigallocatechin gallate Drugs 0.000 description 1
- AVOLMBLBETYQHX-UHFFFAOYSA-N etacrynic acid Chemical compound CCC(=C)C(=O)C1=CC=C(OCC(O)=O)C(Cl)=C1Cl AVOLMBLBETYQHX-UHFFFAOYSA-N 0.000 description 1
- 229960003199 etacrynic acid Drugs 0.000 description 1
- 229960005293 etodolac Drugs 0.000 description 1
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229960002297 fenofibrate Drugs 0.000 description 1
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- ADAUKUOAOMLVSN-UHFFFAOYSA-N gallocyanin Chemical compound [Cl-].OC(=O)C1=CC(O)=C(O)C2=[O+]C3=CC(N(C)C)=CC=C3N=C21 ADAUKUOAOMLVSN-UHFFFAOYSA-N 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 102000028718 growth factor binding proteins Human genes 0.000 description 1
- 108091009353 growth factor binding proteins Proteins 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- HYFHYPWGAURHIV-UHFFFAOYSA-N homoharringtonine Natural products C1=C2CCN3CCCC43C=C(OC)C(OC(=O)C(O)(CCCC(C)(C)O)CC(=O)OC)C4C2=CC2=C1OCO2 HYFHYPWGAURHIV-UHFFFAOYSA-N 0.000 description 1
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 1
- 229960004171 hydroxychloroquine Drugs 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000003617 indole-3-acetic acid Substances 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 102000007236 involucrin Human genes 0.000 description 1
- 108010033564 involucrin Proteins 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 150000004715 keto acids Chemical class 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
- 229960004752 ketorolac Drugs 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 229940116871 l-lactate Drugs 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 108010079309 loricrin Proteins 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229940071648 metered dose inhaler Drugs 0.000 description 1
- IBKQQKPQRYUGBJ-UHFFFAOYSA-N methyl gallate Natural products CC(=O)C1=CC(O)=C(O)C(O)=C1 IBKQQKPQRYUGBJ-UHFFFAOYSA-N 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000004065 mitochondrial dysfunction Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000006540 mitochondrial respiration Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- YAISOECYKYATLL-UHFFFAOYSA-N n-([1,3]thiazolo[5,4-e][1,3]benzothiazol-2-yl)naphthalene-2-carboxamide Chemical compound C1=CC=CC2=CC(C(NC=3SC4=C5N=CSC5=CC=C4N=3)=O)=CC=C21 YAISOECYKYATLL-UHFFFAOYSA-N 0.000 description 1
- DFPMSGMNTNDNHN-ZPHOTFPESA-N naringin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC=2C=C3O[C@@H](CC(=O)C3=C(O)C=2)C=2C=CC(O)=CC=2)O[C@H](CO)[C@@H](O)[C@@H]1O DFPMSGMNTNDNHN-ZPHOTFPESA-N 0.000 description 1
- 229940052490 naringin Drugs 0.000 description 1
- 229930019673 naringin Natural products 0.000 description 1
- MQYXUWHLBZFQQO-UHFFFAOYSA-N nepehinol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C MQYXUWHLBZFQQO-UHFFFAOYSA-N 0.000 description 1
- 230000002988 nephrogenic effect Effects 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 210000003757 neuroblast Anatomy 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 230000005937 nuclear translocation Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- HYFHYPWGAURHIV-JFIAXGOJSA-N omacetaxine mepesuccinate Chemical compound C1=C2CCN3CCC[C@]43C=C(OC)[C@@H](OC(=O)[C@@](O)(CCCC(C)(C)O)CC(=O)OC)[C@H]4C2=CC2=C1OCO2 HYFHYPWGAURHIV-JFIAXGOJSA-N 0.000 description 1
- 229960002230 omacetaxine mepesuccinate Drugs 0.000 description 1
- 230000000771 oncological effect Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000000065 osmolyte Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 231100000262 ototoxicity Toxicity 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 102100032579 p21-activated protein kinase-interacting protein 1 Human genes 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 150000002966 pentacyclic triterpenoids Chemical class 0.000 description 1
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 235000009048 phenolic acids Nutrition 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229960001163 pidotimod Drugs 0.000 description 1
- 150000003058 platinum compounds Chemical class 0.000 description 1
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 description 1
- 230000012354 positive regulation of binding Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 210000004986 primary T-cell Anatomy 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 239000003881 protein kinase C inhibitor Substances 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- BXNMTOQRYBFHNZ-UHFFFAOYSA-N resiquimod Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CC(C)(C)O)C3=C(N)N=C21 BXNMTOQRYBFHNZ-UHFFFAOYSA-N 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 150000004508 retinoic acid derivatives Chemical class 0.000 description 1
- 229910052707 ruthenium Inorganic materials 0.000 description 1
- ILRCGYURZSFMEG-RQICVUQASA-N salidroside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1OCCC1=CC=C(O)C=C1 ILRCGYURZSFMEG-RQICVUQASA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 229950007873 sobetirome Drugs 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 1
- FIWQZURFGYXCEO-UHFFFAOYSA-M sodium;decanoate Chemical compound [Na+].CCCCCCCCCC([O-])=O FIWQZURFGYXCEO-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 229960000894 sulindac Drugs 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000011191 terminal modification Methods 0.000 description 1
- QZZGJDVWLFXDLK-UHFFFAOYSA-N tetracosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCCCC(O)=O QZZGJDVWLFXDLK-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960002175 thyroglobulin Drugs 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- XGOYIMQSIKSOBS-UHFFFAOYSA-N vadimezan Chemical compound C1=CC=C2C(=O)C3=CC=C(C)C(C)=C3OC2=C1CC(O)=O XGOYIMQSIKSOBS-UHFFFAOYSA-N 0.000 description 1
- 229950008737 vadimezan Drugs 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- XLTFNNCXVBYBSX-UHFFFAOYSA-N wogonin Chemical compound COC1=C(O)C=C(O)C(C(C=2)=O)=C1OC=2C1=CC=CC=C1 XLTFNNCXVBYBSX-UHFFFAOYSA-N 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 150000003732 xanthenes Chemical class 0.000 description 1
- 150000007964 xanthones Chemical class 0.000 description 1
- 239000002676 xenobiotic agent Substances 0.000 description 1
- 230000002034 xenobiotic effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4743—Insulin-like growth factor binding protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1754—Insulin-like growth factor binding proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/105—Insulin-like growth factors [IGF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4745—Insulin-like growth factor binding protein
Definitions
- This invention relates to the field of peptide therapeutics, and more particularly to the use of synthetic “immodulin” peptides (also optionally referred to as “immodulator peptides”) to selectively increase the abundance of two or more cooperating mammalian cell lineages in vivo or ex vivo.
- Cooperating lineages may include cells involved in the arbitration of inflammation (e.g. macrophages) followed, programmatically, by the regeneration of new cells in the same tissue.
- the compositions and methods provided herein demonstrate new and surprising uses of immodulin peptides for the regeneration of tissues in mammals.
- This invention provides synthetic immodulin peptides, originally derived from the sequences of classical insulin growth factor binding proteins (IGFBPs 1 through 6), and related compositions and methods.
- IGFs Insulin-like growth factors
- the peptides of this invention are derived from less than 10% of the IGFBP amino acid sequence(s) and do not themselves bind IGFs.
- the effects of the synthetic immodulin peptides of this invention are unrelated to the effects of IGFs themselves.
- IGF-independent effects of classical IGFBPs have been known for decades, but there is no report of (IGF-independent) effects of IGFBP-derived peptides on monocyte differentiation, for example.
- tissue regeneration requires the coordinated action of multiple cell types. For example, certain myeloid lineages (notably macrophages specialized for anti-inflammatory and pro-efferocytotic functions) interact with tissue-resident precursor lineages for differentiation into roles vacated by cells that have recently succumbed to insult, such as ischemic, oxidative or inflammatory insult.
- the synthetic immodulin peptides disclosed herein exhibit new and surprising biological effects on cellular differentiation, such as the stimulation of differentiated myeloid lineages that coordinate the disposal, re-programming and de novo differentiation of adult non-myeloid lineages from precursor cell populations in the tissue.
- compositions and methods are disclosed herein for increasing the abundance of CD169+, CCL22+, and Clec12a+ cross-presenting myeloid lineages by contacting precursor cells in vivo or ex vivo with synthetic immodulin peptides, while also independently stimulating other, non-myeloid cell types in the tissue, such as myoblasts, to differentiate into complementary roles consistent with tissue regeneration and homeostasis.
- IGFBPs Such complementary myeloid and non-myeloid cell differentiation activities have never been disclosed for IGFBPs or for IGFBP-derived synthetic peptides.
- IGFBP-3 and IGFBP-3-derived peptides there is no disclosure of stimulation of differentiation of a specific monocytic or myogenic lineage using synthetic peptides derived from IGFBP-3 (or other classical IGFBP).
- the present invention describes the use of synthetic immodulin peptides to increase the abundance of mammalian cell lineages within a living animal or in a population of mammalian cells derived from an animal (i.e. in vivo or ex vivo). Importantly, the action of these peptides is IGF-independent, as these peptides do not bind IGFs. Cells treated with synthetic immodulin peptides ex vivo may subsequently be re-introduced into a living mammal.
- hematopoietic or other mesenchymal cell lineages can be expanded so as to improve outcomes in cancer therapy, targeted vaccination, management of traumatic insults, anemia, neurodegeneration, regeneration of tissues, and prevention of medical complications from diseases such as obesity, diabetes, and diseases of aging.
- Synthetic immodulin peptides are believed to rapidly target and enter cells under stress, move to specific cellular compartments (e.g. the nucleus, cytoplasm, mitochondria), and interact with cellular machinery in different ways. For example, they can bind transcriptional factors and thereby alter large transcriptional sets.
- IGFBP-derived synthetic sequences to increase the abundance of differentiation markers in myeloid hematopoietic cell lineages (such as CD169+, CCL22+ or Clec12a+ monocytes, dendritic cells and macrophages) or in non-myeloid lineages important in re-establishment of tissue homeostasis (such as myoblasts, osteoblasts, chondroblasts, neuroblasts, fibroblasts and lymphocytes has never been disclosed. Indeed, to the inventor's knowledge, no other peptide molecule has ever been identified that is capable of such function.
- the peptides of this invention are uniquely useful, for example, in the treatment of acute (driven by traumatic insult or myocardial infarction, for example) and chronic inflammatory skeletal myopathies, which have themselves been shown to trigger neurodegeneration, kidney disease, heart failure, COPD, and many of the degenerative conditions associated with aging. Numerous other applications secondary to reversing inflammatory loss of skeletal muscle will be readily apparent to skilled practitioners in the field.
- Retinoid X receptors are promiscuous heterodimeric partners for other members of the Nuclear Receptor (NR) superfamily including members of the NR1 group, which include thyroid receptors (TRs), retinoic acid receptors (RARs), peroxisome proliferator-activated receptors (PPARs), LXRs, FXR and many others; NR3 group (ERs, GR, MR, PR, AR); NR4 (notably NR4A1/Nur77); and members of other NR groups.
- TRs thyroid receptors
- RARs retinoic acid receptors
- PPARs peroxisome proliferator-activated receptors
- LXRs LXRs
- FXR FXR and many others
- NR3 group ERs, GR, MR, PR, AR
- NR4 notably NR4A1/Nur77
- RXRs are obligatory partners for a number of NR partners, placing RXRs in a coordinating role at the crossroads of multiple signaling pathways.
- RXRs represent important targets for pharmacologic interventions and therapeutic applications.
- RXRs function as master regulators producing diverse physiological effects through the activation of multiple nuclear receptor complexes.
- Immodulin peptides bind RXRs and Nur77 in vitro, and appear to guide heterodimer formation.
- RXR agonists alone, partner receptor agonists alone or a combination of both can activate dimers, including permissive heterodimers.
- Such complexes include those formed with PPARs such as PPAR ⁇ , PPAR ⁇ PPARd PPAR ⁇ ), FXR (farnesoid X receptor), LXR (liver X receptor), and the orphan NR4A group, including Nur77 and Nurr1.
- PPARs such as PPAR ⁇ , PPAR ⁇ PPARd PPAR ⁇
- FXR farnesoid X receptor
- LXR liver X receptor
- orphan NR4A group including Nur77 and Nurr1.
- Nur77 and Nurr1 transcriptional activities can be indirectly manipulated through modulation of their heterodimeric partner RXR, using ligands such SR11237, BRF110, HX531 or HX600, or other RXR/NR4A ligands and modulators such as spironolactone, haloperidol, cytosporone B, C-DIM12, C-DIM8 and cilostazol; PPAR ligands such as fenofibrate, fenofibric acid, ciprofibrate, gemfibrozil, clofibric acid, elafibrinor, GW9578, RB394, MBX-8025, GW7647, ZLY032, GW590735, GW0742, GW501516 and Amorfrutin B; and NR ligands such as BMS195614, GW4064, BMS453, sobetirome, ciloflexor, TTNPB
- Classical IGFBPs from which the core sequences of the immodulin peptides of this invention are derived, are a highly conserved family of proteins, both structurally and functionally.
- the sequence of IGFBPs 3, 5 and 6 from which the peptides of this invention are derived are particularly closely conserved.
- These three IGFBPs form a major evolutionary Glade that diverged from IGFBPs 1, 2 and 4 more than 700 million years ago. Functional features present in the 3/5/6 Glade and not in the 1/2/4 Glade include metal binding, PIP2-binding and nuclear transport.
- Amino acid sequence identity in the C-terminal thyroglobulin type-1 domain from which the sequences of the immodulin peptides of this invention are derived is higher within the 3/5/6 IGFBP Glade (for example, 59% between IGFBP-3 and -5, but only 31% between IGFBP-1 and -5).
- No synthetic immodulin peptide binds IGFs.
- Each immodulin sequence represents less than 10% of the original IGFBP sequence from which it derives. It would be surprising if an immodulin retained any of the biological activities of the IGFBP molecule, let alone allow prediction of which.
- IGFBP proteins alone were successfully used to drive differentiation of mammalian monocyte, myogenic, osteogenic and lymphocytic lineages, and knows of no other peptide in biology that can do so.
- the immodulin peptide -3, -5 and -6 core sequences of this invention are highly related and comprise, respectively:
- Immodulin peptides naturally bind iron and holotransferrin, a major iron-carrier in the circulation.
- This invention provides holotransferrin-bound immodulin peptide capable of discriminating phosphatidylinositol 4,5-bisphosphate (PIP2)-rich membrane domains.
- Immodulins 3/5/6 bind PIP2, which competes with transferrin for binding to peptides.
- Holotransferrin-bound immodulin 3 or 5 selectively binds high-molecular weight hyaluronan (HMW-HA) more strongly than low-molecular weight hyaluronan (LMW-HA), a key discriminant in selective delivery in vivo, as LMW-HA has been widely associated with inflammatory effects, whereas HMW-HA has been associated with anti-inflammatory effects of hyaluronan.
- Hyaluronan is an abundant glycosaminoglycan ubiquitously present in the extracellular matrix of cell targets. Even more surprisingly, low endocytic pH dramatically increases binding of holotransferrin-immodulin complex to HMW-HA, but not LMW-HA.
- the master receptor, CD44, a hyaluronan receptor associated with cellular architecture and differentiation binds this holotransferrin-immodulin-HMW-HA trimeric complex in vitro.
- CD44 a hyaluronan receptor associated with cellular architecture and differentiation
- the intrinsic nuclear translocation and iron-binding properties of immodulins may provide a mechanistic link to the profound influences exerted by immodulins in the context of tissue regeneration.
- the synthetic peptides of the present invention thus benefit from selective carriage to target cells (such as mesenchymal cells under stress, as shown in references provided), selective uptake by receptors located in favorable membrane domains (such as PIP2-rich domains), selective transfer to a glycan carrier under the low pH conditions of an endocytic environment (such as HMW-HA and HMW-HA::CD44 complex), efficient nuclear import (using the nuclear import sequence contained in the immodulin peptides, as detailed in th references), and the ability to access chromatin wherein RXRs can control transcriptional programs (by stimulation of binding in heterodimeric complexes with NR partners, or by modification of kinase or HDAC activity, for example, as shown in priority documents and in this document).
- target cells such as mesenchymal cells under stress, as shown in references provided
- receptors located in favorable membrane domains such as PIP2-rich domains
- a glycan carrier under the low pH conditions of an endocytic environment
- This invention discloses new compositions and new or improved utilities for the immodulin peptide class. Sequence extensions to immodulin core sequences disclosed in the invention confer new biological activities useful in treating human disease and in cosmetics. Previously known utilities of immodulin peptides are described, for example, in PCT/US2020/024828, PCT/US2021/021433, PCT/US2021/046814, U.S. Pat. Nos. 5,519,003/5,783,405/6,165,977/6,262,023/6,342,368/6,423,684/6,855,693/6,933,275/7,393,835/8,536,135/10,369,1919; and references cited therein. These are all hereby incorporated by reference.
- Methods disclosed in this invention include the administration of pharmaceutical compositions containing immodulin peptides to a mammal showing symptoms that may be linked to disease conditions, including but not limited to metabolic, muscle-wasting, neurodegenerative and cardiovascular diseases (especially those characterized by some underlying combination of insulin resistance, hyperglycemia, hypertension or hyperlipidemia); immune response to targeted vaccination, cancer progression and metastasis, pulmonary distress and acute kidney injury (AKI) in critical care settings, sepsis, anemia, systemic inflammatory conditions such as shock, post-operative oxidative stress such as after cardiopulmonary bypass or transplant, burns, blunt trauma, pancreatitis, rhabdomyolysis, xenobiotic stresses caused by cocaine, nicotine, alcohol, aminoglycoside antibiotics, cyclosporins, antiviral compounds or chemotherapeutic agents such as platinum compounds or doxorubicin; neuropathic pain and migraine; neurodegenerative diseases such as major depression, Parkinson's, Alzheimer's, Huntington's and ALS/Lou Gehrig
- the invention provides a synthetic peptide, 20-60 amino acids in length, comprising: (i) a core immodulin sequence corresponding to any one of SEQ ID NOs:1-6; and, optionally, (ii) a small molecule of molecular mass less than one thousand daltons linked covalently to the amino terminus of the peptide.
- the small molecule is selected from the group consisting of: oleic acid, lauric acid, 2-hydroxy-2-decenoic acid, phenolic acids, anthraquinones, pentacyclic triterpenoids, retinoic acids, bexarotene and other rexinoids, rhein, proprionic acids, TLR4 inhibitors, keto acids, cinnamic acids, aromatic carboxylic acids, indoleacetic acids, xanthenes, xanthones, 2,7-dichlorodihydro-fluorescein diacetate, indolyl-carboxylic acids, PF-06409577, AICAR, D942, PT1, EX-229, GIT27, GW501516, GW3965, GW9578, RB394, MBX-8025, GW7647, ZLY032, GW590735, GW0742, Amorfrutin B, BMS195614, GW40
- a synthetic immodulin peptide is complexed or co-administered with a metal selected from the group consisting of: ferrous iron, ferric iron, zinc, copper, ruthenium, cobalt, titanium and calcium.
- a synthetic immodulin peptide described herein is complexed or co-administered with a glycosaminoglycan or other extracellular matrix component including a group consisting of: collagen, transferrins, other iron-binding proteins, heparin, heparan sulfate, chondroitin sulfate, keratan sulfate, dermatan sulfate, and hyaluronate.
- a synthetic immodulin peptide described herein is co-administered with a helper molecule selected from a group consisting of: phytochemicals, ornithine, leucine, raffinose sugar, trehalose sugar, avocado sugar, lactate, bile salts, cyclodextrin, resveratrol, polydatin, ursolic acid and cyclic dinucleotides.
- helper molecule selected from a group consisting of: phytochemicals, ornithine, leucine, raffinose sugar, trehalose sugar, avocado sugar, lactate, bile salts, cyclodextrin, resveratrol, polydatin, ursolic acid and cyclic dinucleotides.
- the invention provides a pharmaceutical composition that includes any synthetic immodulin peptide or peptide complex described herein, and a pharmaceutically acceptable excipient.
- the invention provides a method for treating a subject suffering from immunological, neurological, myopathic, oncologic, skeletal, reproductive, metabolic or cosmetic dysfunction or imbalance, where the method includes administering to the subject (e.g., a human subject) a therapeutically effective dose of a synthetic immodulin peptide or immodulin peptide/helper molecule complex, or a pharmaceutical composition as described herein.
- the therapeutically effective dose of the synthetic immodulin peptide is from about 0.01 mg/kg/day to about 50 mg/kg/day.
- the invention provides an in vitro method for using cultured mammalian cells to measure the potency of any immodulin peptide described herein.
- compositions of the invention may be administered by means that include but are not limited to intravenous, oral, subcutaneous, intraarterial, intramuscular, intracardial, intraspinal, intrathoracic, intraperitoneal, sublingual, transdermal, intranasal and by inhalation.
- subject and “individual”, as used herein, refer to mammalian individuals, and more particularly to pet animals (e.g., dogs, cats), agricultural animals (e.g., cows, horses, sheep, and the like), and primates (e.g., humans).
- pet animals e.g., dogs, cats
- agricultural animals e.g., cows, horses, sheep, and the like
- primates e.g., humans.
- treatment is used herein as equivalent to the term “alleviating”, which, as used herein, refers to an improvement, lessening, stabilization, or diminution of a symptom of a disease or immune imbalance. “Alleviating” also includes slowing or halting progression of a symptom.
- co-administration refers to administration of one treatment modality in addition to another treatment modality.
- in conjunction with refers to administration of one treatment modality just before, during or soon after delivery of the other treatment modality to the subject.
- synthetic immodulin peptide shall mean a peptide molecule 20-60 amino acids in length prepared by chemical synthesis and comprising any of SEQ ID NOs:1-6.
- phytochemical shall include D-heptomannulose, trehalose, naringin, resveratrol, polydatin, plumbagin, quercetin, curcumin, berberine, alpha-mangostin, wogonin, and ursolic acid.
- RXR ligand-like compound
- conjugates include all ligands of RXRs, and conjugates thereof.
- bexarotene-class rexinoid shall include bexarotene, LG100268, SR11237, HX600, HX531, BRF110 and conjugates thereof.
- NSAID includes ibuprofen, sulindac (and its sulfide and sulfone derivatives), indomethacin, aspirin, naproxin, ketoprofen, ketorolac, diclofenac and etodolac, and conjugates thereof.
- RLR/STING/IFN-class agonist shall include cyclic dinucleotides such as 2′3′cGAMP and cyclic di-GMP, nucleotides such poly-I:C and double-stranded ppp-RNA, and small molecule agonists such as G10, KIN1400, KIN1408, KIN 1148, R08191, MSA-2, SR-717, alpha-mangostin, DMXAA and conjugates thereof.
- N4A-class ligand shall include spironolactone, haloperidol, cytosporone B, C-DIMS, C-DIM8, C-DIM12, cilostazol, PDNPA and conjugates thereof.
- immunomodulant-class molecule shall include GIT-27, Schisandrin A, resiquimod (R-848), hydroxychloroquine, pidotimod, itraconazole, homoharringtonine, salidroside, celastrol, zymostenol, 7-dehydrocholesterol and conjugates thereof.
- Wnt-class molecule shall include gallic acid, methyl gallate, gallocyanine, epigallocatechin gallate, XAV939, ethacrynic acid, leonurine and conjugates thereof.
- “Significantly increasing the abundance of a mammalian cell lineage differentiation marker” shall mean increasing the relative average abundance of the cell lineage differentiation marker in the population of cells contacted with synthetic immodulin peptide by at least fifteen percent over an untreated population control, such that the average difference between the two populations is statistically significant—for example, with a calculated probability of p ⁇ 0.05 using Student's T-test, or other comparable statistical test, well known to those skilled in the art.
- “Differentiated mammalian cell lineage” means a living mammalian cell population expressing markers and/or functions characteristic of a differentiated cell type.
- “In vivo” treatment means treatment within a living animal.
- Ex vivo treatment means treatment of a mammalian cell population after its removal from an animal. Ex vivo-treated cells may optionally be re-introduced into the animal.
- Precursor cell in the context of the invention, means a living mammalian cell capable of cellular differentiation. Quantitation of a marker can be made using commercially available kits for such a marker. The kits may measure different aspects of such a marker, such as gene expression, protein abundance, protein activity and biochemical or clinical consequences thereof.
- “Significantly altering the relative abundance or bioactivity of a marker” means changing the average abundance or biological activity of a protein, mRNA, carbohydrate, lipid, metabolite or other biological analyte whose changed abundance or bioactivity is measurable in a population of cells by practitioners skilled in the art using commercially available kits, wherein the change is shown to occur to a statistically significant degree in cells treated by the methods of this invention compared to a control population.
- the difference between average measured abundance or bioactivity of a marker is significantly different in a population of cells that received treatment by the methods of this invention (as compared to an untreated control population of cells) if the difference between the two populations is statistically significant, for example, with a calculated probability of p ⁇ 0.05 using Student's T-test, or other comparable statistical test well known in the art.
- the abundance or bioactivity of a marker such as a protein or RNA known to be diagnostic for the differentiated cell population in question, can be readily measured using commercially available test kits, well-known and widely used in the field e.g. ELISA kits, qPCR kits, enzymatic activity kits, etc.
- Test kits can be purchased for cell surface markers such as CD169, Clec9a, Clec10a, Clec12a, CD205, CD207, CD209, CD209L and MHCII, secreted proteins such as IL-10, TGFbeta, TNFalpha, CCL22 and COL1A1 (collagen), and nuclear proteins such as FoxP3, Nur77/NR4A1, RXRs, PPARs and other modulators of transcrition.
- cell surface markers such as CD169, Clec9a, Clec10a, Clec12a, CD205, CD207, CD209, CD209L and MHCII
- secreted proteins such as IL-10, TGFbeta, TNFalpha, CCL22 and COL1A1 (collagen)
- nuclear proteins such as FoxP3, Nur77/NR4A1, RXRs, PPARs and other modulators of transcrition.
- RXR means retinoid X receptor, and can refer to either the RXR gene or the protein it specifies.
- Rexinoid means a ligand of an RXR receptor.
- RXRs means any of the RXR isoforms, such as RXR-alpha, RXR-beta, RXR-gamma, and also covers heterodimers formed between them and other nuclear receptors such as NR4As.
- NR4As includes the orphan nuclear receptors NR4A1, NR4A2 and NR4A3, and can refer to either the NR4A gene or the protein it specifies.
- RXR receptors can and do form functional heterodimers with a variety of other nuclear receptors such as retinoic acid receptors (RARs), thyroid receptors (TRs), vitamin D receptor (VDR), liver X receptors (LXRs), peroxisome proliferator-activated receptors (PPARs), and the aforementioned NR4As.
- RARs retinoic acid receptors
- TRs thyroid receptors
- VDR vitamin D receptor
- LXRs liver X receptors
- PPARs peroxisome proliferator-activated receptors
- CD169 also known as Siglec-1
- Siglec-1 sialoadhesin, a cell adhesion molecule found on the surface of macrophages. Orthologs of this molecule in other mammalian species are included in this definition.
- C-lectins means a C-type lectin such as Clec4a, Clec9a, Clec10a or Clec12a, and orthologs thereof.
- CCL22 (also known as MDC) means C-C motif chemokine 22, and its orthologs.
- COL1A1 means alpha-1 Type I collagen.
- STING means “stimulator of interferon genes. STING is also known as TMEM173.
- “Nur77” is the protein product of the NR4A1 gene. As an analyte, the two terms are here used interchangeably. Sometimes the gene product may be referred to as Nur77/NR4A1 or NR4A1/Nur77.
- This invention provides a method for stimulating levels of differentiation markers in myeloid and non-myeloid mammalian cell lineages in vivo or ex vivo, the method comprising: (i) contacting one or more mammalian cells of a myeloid lineage with a synthetic immodulin peptide about 20 to about 60 amino acids in length and comprising an amino acid sequence corresponding to any one of SEQ ID NOs:1-6; and (ii) contacting one or more mammalian cells of a non-myeloid lineage with said synthetic immodulin peptide; and (iii) measuring a readout of differentiation for the myeloid mammalian cell lineage wherein said readout is accompanied by a significantly increased average level of at least one marker for myeloid lineage differentiation in the contacted cells of the myeloid lineage; and (iv) measuring a readout of differentiation for the non-myeloid mammalian cell lineage wherein said readout is accompanied by a significantly increased average level of at least one marker for non-
- cells of said myeloid and non-myeloid lineages following the contacting steps may come to be co-resident in a living tissue by contacting the synthetic immodulin peptide to each lineage separately or concurrently, wherein “concurrently” shall mean simultaneously, at approximately the same time, or in immediate or overlapping sequence, and having any of the contacting steps take place either in vivo or ex vivo.
- Non-myeloid lineages may include cells of a neurogenic lineage, wherein the readout is neurogenesis, and the marker for differentiation is selected from the group consisting of: synaptophysin, synaptopodin, vimentin, NMDAR, AChR, and PSD95.
- Non-myeloid lineages may also include cells of a myogenic lineage, wherein the readout is myogenesis, and the marker for differentiation is selected from the group consisting of: creatine kinase, myogenin, MYF-4, MYF-5 and actinin-2.
- Myogenesis includes formation of myotubes as well as higher order structures.
- Non-myeloid lineages may also include cells of an osteogenic lineage, wherein the readout is osteogenesis, and the marker for differentiation is selected from the group consisting of: alkaline phosphatase, calcified deposits, osteocalcin and BMP-2.
- Non-myeloid lineages may also include cells of a chondrogenic lineage, wherein the readout is chondrogenesis, and the marker for differentiation is selected from the group consisting of: type II collagen, aggrecan and Sox 9.
- Non-myeloid lineages may also include cells of a keratinocytic lineage, wherein the readout is differentiated keratinocytes and the marker of differentiation is selected from the group consisting of keratin-10, profilaggrin, loricrin and involucrin.
- Non-myeloid lineages may also include cells of a lymphocytic lineage, wherein the readout is differentiated lymphocytes and the marker of differentiation is selected from the group consisting of FoxP3 and IL-10.
- Non-myeloid lineages may also include cells of a pulmonary lineage, wherein the readout is differentiated pulmonary cells and the marker of differentiation is selected from the group consisting of NKX2.1, HOPX, GPRC5A, AGER or AQP5.
- Non-myeloid lineages may also include cells of a fibroblastic lineage, wherein the readout is differentiated fibroblasts and the marker of differentiation is COL1A1.
- Non-myeloid lineages may also include cells of a nephrogenic lineage, wherein the readout is differentiated kidney cells and the marker of differentiation is selected from the group consisting of CALB1, AQP2, AVPR2 and PENDRIN.
- Non-myeloid lineages may also include cells of a hepatogenic lineage, wherein the readout is differentiated liver cells and the marker of differentiation is selected from the group consisting of AAT1, alpha-fetoprotein, HNF-4a, glycogen and albumin.
- a “readout” may refer to a gene readout (for example, gene transcription), a protein readout (for example by ELISA, or enzymatic assay), a biochemical readout (for example, by assay of a molecule that is not a nucleic acid, peptide or protein) or a functional readout (for example by clinical readout of a patient's symptoms).
- Transcription can be quantitated in mammalian cells or tissues by techniques such as quantitative PCR (qPCR).
- kits can measure levels of analytes, both protein and non-protein.
- a clinician's expertise facilitates assessment of a patient's symptoms. For examples, changes in grip strength can be measured with a dynamometer. Body temperature may be measured using a thermometer.
- This invention also provides a peptide having an amino terminus formed by covalent linkage to a “small molecule” of molecular mass less than one thousand daltons, preferably less than five hundred daltons.
- Said “small molecule” is selected from the group consisting of PF-06409577, AICAR, D942, PT1, EX-229, GIT27, GW501516, GW3965, GW9578, RB394, MBX-8025, GW7647, ZLY032, GW590735, GW0742, Amorfrutin B, BMS195614, GW4064, BMS453, FTY720, artesunate, sobetirone, cilofexor, decanoic acid, eicosapentaenoic acid, docosahexanoic acid, lignoceric acid, TTNPB, adapalene, bexarotene, transcinnamic acid, fenofibri
- the invention also provides a synthetic immodulin peptide comprising a core sequence selected from the group consisting of any of SEQ ID NOs: 1-6.
- said core sequence is aminoterminally extended by a sequence comprising any of sequence ID NOs: 7-14.
- the invention provides kinase modulating sequences to be used in conjunction with the immodulin sequences of this invention.
- Kinase inhibitor peptides have been widely used by practitioners in the field for several decades.
- U.S. Pat. No. 5,783,405 lists dozens of peptide sequences and teaches their use as protein kinase C inhibitors.
- sequences AFNSYELGS and SLNPEWNET claimed to inhibit PKC-delta and PKC-beta, respectively, as well as PKC-epsilon stimulating sequences such as NGLLKIK.
- the invention provides a synthetic immodulin peptide in a complex with non-covalently bound, purified holotransferrin at about 0.1 to about 10 molar equivalents of one to the other.
- Holotransferrin is transferrin in which at least one of the iron-binding sites is occupied by ferric iron.
- the peptide-holotransferrin binary complex provides better targeting of the synthetic immodulin peptide in vivo by virtue of its preferential binding to high-molecular weight size classes of glycosaminoglycans, notably hyaluronan (HMW-HA) which are, in turn, taken up by the receptor CD44 in preferred contexts.
- HMW-HA high-molecular weight size classes of glycosaminoglycans
- preferential binding of the binary complex to PIP2 which is enriched in preferred cellular membrane contexts for resolution of inflammation and cellular differentiation, may also (and independently) increase specificity of targeting in vivo.
- the invention provides a synthetic immodulin peptide in a complex with non-covalently bound, purified holotransferrin at about 0.1 to about 10 molar equivalents of one to the other, additionally complexed to HMW-HA at about 0.01 to about 100 molar equivalents of purified high-molecular weight hyaluronan relative to peptide.
- the stability of this ternary complex is stronger at pH 5.2 (endocytic pH) than at pH 7.4, the physiological pH in most cellular compartments.
- the stability of this ternary complex containing HMW-HA is stronger than the corresponding ternary complex containing LMW-HA. Size classes of hyaluronan are thought to play key roles in inflammation.
- the invention provides compositions comprising said ternary complex.
- the invention provides a method for treating a mammal showing symptoms of immune dysfunction or imbalance comprising administering to said mammal via intramuscular, subcutaneous, parenteral, transdermal, intranasal, intravenous or intrathecal route of administration a pharmaceutical formulation comprising a therapeutically effective dose of an immodulin peptide according to the invention, and a pharmaceutically acceptable excipient, thereby alleviating said symptoms of dysfunction.
- the immodulin peptide is administered in a therapeutically effective dose of peptide between about 0.01 mg/kg/day to about 50 mg/kg/day.
- the invention provides for co-administration of a helper molecule selected from a group consisting of: ornithine, leucine, raffinose, trehalose, resveratrol, polydatin, ursolic acid, lactate, bile salt, metal, cyclodextrin and cyclic dinucleotide.
- a helper molecule selected from a group consisting of: ornithine, leucine, raffinose, trehalose, resveratrol, polydatin, ursolic acid, lactate, bile salt, metal, cyclodextrin and cyclic dinucleotide.
- This invention envisages an in vitro method for measuring cell differentiating potency of a synthetic immodulin peptide, the method comprising measurement of the abundance of a marker selected from the group consisting of PPARs, RXRs, NR4As, CD169, CCL22, IL-10, TGFbeta, FoxP3, C-lectins, COL1A1, TNFalpha, NfkappaB, MMP-9, IL-6, STING, interferons, RLRs or toll-like receptors in cultured mammalian cells that have been treated with the synthetic peptide.
- a marker selected from the group consisting of PPARs, RXRs, NR4As, CD169, CCL22, IL-10, TGFbeta, FoxP3, C-lectins, COL1A1, TNFalpha, NfkappaB, MMP-9, IL-6, STING, interferons, RLRs or toll-like receptors in cultured mamma
- the signal may be measured using a fluorometer. If a chemiluminescent detection system is used, then the signal can be detected using a luminometer. Either gene expression (via qPCR) or protein levels and/or enzymatic activity may be measured. Methods for detecting signal from detection systems for such analytes are well known in the art and need not be further described here.
- sequence “identity” and “homology”, as referred to herein, can be determined using BLAST, particularly BLASTp as implemented by the National Center for Biotechnology Information (NCBI), using default parameters. It will be readily apparent to a practitioner skilled in the art that sequences claimed hereunder include all homologous and trivial variants of an immodulin peptide, such as by conservative substitution, extension and deletion in amino acid sequence. Trivial substitution variants include swapping of an amino acid with another belonging to the same class, without such substitution resulting in statistically and functionally significant change.
- “Classes” of amino acids include positively charged amino acids (arginine, lysine, histidine), negatively charged amino acids (aspartic acid, glutamic acid), aromatic amino acids (tyrosine, phenylalanine, tryptophan), branched chain amino acids (valine, leucine isoleucine) and other natural groupings such as (serine, threonine) and (asparagine, glutamine).
- such conservative substitutions to immodulin sequences if they do not create a significant change in function, are considered equivalent to the original and are covered by the scope of this invention.
- an effective amount of therapeutic agent is administered to a subject having a disease.
- the agent is administered at about to about 50 milligrams per kilogram total body weight per day (mg/kg/day).
- the agent is administered at about 0.001 to about 50 mg/kg/day, e.g., 0.01, 0.015, 0.02, 0.05, 0.1, 0.2, 0.5, 0.7, 1, 2, 4, 5, 7, 9, 10, 15, 25, 30, 35 or another dose from about 0.001 mg/kg/day to about 50 mg/kg/day.
- Therapeutic agents are preferably administered via oral or parenteral administration, including but not limited to intravenous (IV), intra-arterial (IA), intraperitoneal (IP), intramuscular (IM), intracardial, subcutaneous (SC), intrathoracic, intraspinal, intradermal (ID), transdermal, oral, sublingual, inhaled, and intranasal routes.
- IV, IP, IM, and ID administration may be by bolus or infusion administration.
- SC administration administration may be by bolus, infusion, or by implantable device, such as an implantable minipump (e.g., osmotic or mechanical minipump) or slow release implant.
- the agent may also be delivered in a slow release formulation adapted for IV, IP, IM, ID or SC administration.
- Inhaled agent is preferably delivered in discrete doses (e.g., via a metered dose inhaler adapted for protein delivery).
- Administration of a molecule comprising an agent via the transdermal route may be continuous or pulsatile.
- Administration of agents may also occur orally.
- compositions comprising a therapeutic agent may be in dry powder, semi-solid or liquid formulations.
- the composition comprising an agent is preferably administered in a liquid formulation.
- Compositions comprising an agent formulation may contain additional components such as salts, buffers, bulking agents, osmolytes, antioxidants, detergents, surfactants, and other pharmaceutical excipients as are known in the art.
- N-terminally biotinylated versions of the peptides listed below were used in various assays listed in the examples.
- PIP phosphatidylinositon phosphate
- PEPTIDE SEQUENCE None (buffer) imm1 KNGFYHSRQCETSMDGEAGLCW imm2 KHGLYNLKQCKMSLNGQRGECW imm3 KKGFYKKKQCRPSKGRKRGFCW imm4 RNGNFHPKQCHPALDGQRGKCW imm5 RKGFYKRKQCKPSRGRKRGICW imm6 HRGFYRKRQCRSSQGQRRGPCW immX3AVD KKGFYKKKQCRPSKGRKRGFCWAVD immX4AVD RNGNFHPKQCHPALDGQRGKCWAVD immX5AVD RKGFYKRKQCKPSRGRKRGICWAVD immX3dAVD KKGFYKKKQCRPSKGRKRGFCW (dA) VD immX3dAdVdD KKGFYKKKQCRPSKGRKRGFCW (dA)(dV)(dD) immX3dSdVdD
- Mammalian cell differentiation assays employed the THP1-Dual monocyte reporter cell line (Invivogen Inc, San Diego, CA) seeded at 2 ⁇ 10e5 cells per well in 96-well plates and cultured at 37 degrees C. in RPMI-1640 growth medium plus 10% fetal bovine serum and 1% penicillin/streptomycin. Cells were subsequently treated for 24 hours with 100 ng/ml Phorbol 12-myristate 13-acetate (PMA protocol; Cayman Chemical Company, Ann Arbor, MI). Peptide (0.33 uM or 0.66 uM, as indicated) was then added, and incubation continued for an additional 24 hours. Culture supernatants were assayed for CCL22.
- THP1-Dual monocyte reporter cell line Invivogen Inc, San Diego, CA
- PMA protocol Cayman Chemical Company, Ann Arbor, MI
- Peptide (0.33 uM or 0.66 uM, as indicated) was then added, and incubation continued for an additional 24 hours. Culture
- immX3AVD 100 282.4 ⁇ 18.4 100 immX4AVD 1.0 ⁇ 0.3** n.d. n.d. immX5AVD 100.9 ⁇ 3.5 228.6 ⁇ 8.1 n.d. immX3dAVD 104.3 ⁇ 6.1 247.3 ⁇ 16.1 n.d. immX3dAdVdD 183.3 ⁇ 6.4** n.d. 106.6 ⁇ 5.2 immX3dSdVdD 145.7 ⁇ 9.3** n.d. n.d. immX3FVS 109.4 ⁇ 4.5 251.3 ⁇ 5.8 n.d. immX3RVD 88.1 ⁇ 4.2 272.5 ⁇ 35.7 n.d.
- Streptavidin-coated 96-well plates (G-Biosciences, St. Louis, MO) were pre-loaded with biotinylated peptides [see Example 1] at 400 ng/well, at room temperature for 60 minutes. The plate was washed with PBS buffer and then 1 ug FITC-labelled heparin or hyaluronic acid (FITC-HMW-HA) in 100 uL PBS buffer was added per well (all tests done in quadruplicate). Incubation proceeded for 90 minutes at room temperature, followed by two PBS washes.
- FITC-HMW-HA FITC-HMW-HA
- PEPTIDE Heparin Hyaluronate imm2 27.4 ⁇ 22.9 3.1 ⁇ 9.8 imm3 104.2 ⁇ 22.0 57.2 ⁇ 5.7** imm4 6.8 ⁇ 24.1 14.6 ⁇ 22.6 imm5 95.1 ⁇ 25.7 60.0 ⁇ 8.6** imm6 97.2 ⁇ 17.3 44.9 ⁇ 14.1** immX3AVD 100.0 ⁇ 4.7 100.0 ⁇ 22.8 immX4AVD 7.3 ⁇ 17.1 61.1 ⁇ 34.1 immX5AVD 68.7 ⁇ 26.2 113.9 ⁇ 15.7 immX3dAdVdD 55.5 ⁇ 5.7** 104.2 ⁇ 14.7 immX3K1dAdVdD 56.0 ⁇ 7.3** 101.9 ⁇ 16.4
- a third binding experiment was done as described above using immX3AVD peptide with or without 10 ug/well holotransferrin (holoTf) plus either 10 ug/well LMW-HA or either 1.5 ug or 10 ug HMW-HA/well in the binding step, followed by a buffer wash step.
- 100 ng/well pure recombinant CD44 protein (Abcam, Waltham, MA) was then added to the indicated wells, incubated for 60 minutes at room temperature and the plate was washed with buffer.
- PH Peptide CONTROL 1.5 ug/w HMW-HA 10 ug/w HMW-HA 10 ug/w LMW-HA 7.4 None (buffer) 1.5 ⁇ 15.8** n.d. n.d. n.d. 7.4 immX3AVD 19.6 ⁇ 13.0** 100.0 ⁇ 15.5 101.1 ⁇ 4.9 103.0 ⁇ 19.4 7.4 immX3AVD + 3.1 ⁇ 11.5** 98.3 ⁇ 11.0 107.0 ⁇ 1.9 38.7 ⁇ 4.4** holoTf 5.2 None (buffer) 0.9 ⁇ 21.5** n.d. n.d. n.d.
- C2C12 myoblastic cell line (ATCC, Manassas, VA) seeded at 2 ⁇ 10e5 cells per well in 96-well plates and cultured at 37 degrees C. in DMEM growth medium plus 10% fetal bovine serum and 1% penicillin/streptomycin. For differentiation, 10% fetal bovine serum was replaced with 2% horse serum. 0.66 uM peptide was then added, and incubation continued for an additional 96 hours. Plates with adherent cells were washed with PBS, lysed with Lytic-M buffer (Sigma Chemical Company, St.
- PEPTIDE Creatine Kinase Act. Helper molecule None (buffer) 0.7 ⁇ 2.6** none immX3AVD 100.0 ⁇ 2.2 none immX3AVD 120.6 ⁇ 2.5** Tf immX3AVD 136.7 ⁇ 13.3 Tf + LMW-HA (2 ug/ml) immX3AVD 33.2 ⁇ 3.2 # Tf + HMW-HA (2 ug/ml) immX3AVD 161.5 ⁇ 6.5** L-ornithine (1 mM) immX3AVD 140.3 ⁇ 8.3** D-raffinose (1 mM) immX3AVD 174.2 ⁇ 5.0** GW 501516 (2 uM) immX3AVD 67.4 ⁇ 5.2** GW 3965 (2 uM) immX3AVD 109.4 ⁇ 3.2** ciprofibrate (2 uM) immX3dAdVdD 132.8 ⁇ 5.2** none im
- THP1-Dual cells were treated with both GAD65 peptide antigen (1 ug/ml) and immodulin peptide (0.66 uM) using the protocol described in Example 2. After completion of the myeloid cell differentiation step (24 hours), supernatants were collected and 100,000 primary T-cells were added to each well in RPMI-1640 medium (100 uL per well). Plates were incubated for an additional 96 hours and cell extracts were prepared using CellLytic-M reagent (Sigma Chemical Co., St Louis, MO).
- Osteoblast cell line MC3T3E1 was purchased from ATCC (Manassas, VA) and grown in 96-well plates in alpha-MEM medium supplemented with 50 ug/ml ascorbic acid and 5 mM beta-glycerophosphate. Peptides were added and incubation proceeded for 5 days. Cells were washed with PBS buffer and extracts prepared using 100 uL 1X RIPA buffer (Cayman Chemical Company; Ann Arbor, MI) per well.
- PEPTIDE (0.66 uM) Compound added Alk. Phos.
- the reaction mixture was renewed after 2 hrs reaction time and allowed to react another 4 hrs or overnight. After washing the resin several times with DMF, and subsequently with DCM, the batches were dried.
- the resins were treated with 1% DTT, 2% water and 3% TIPS in TFA for 3.5 hrs.
- the cleavage solution was separated from the resin and treated with diethylether/n-pentane (1:1). The resulting precipitate was centrifuged and the pellet washed three times in the same DEE/pentane mixture.
- the recovered peptide was air dried and stored at ⁇ 20 degrees C.
- HFF-1 human fibroblast cell line was obtained from the American Type Culture Collection (ATCC). Cells were grown in a T-75 flask in DMEM Medium containing 10% fetal bovine serum and penicillin-streptomycin at 37° C. in a humidified, 5% CO 2 incubator. Cells (100 ml, 2,000 cells/well) were plated in a 96-well plate and incubated overnight at 37° C. in a humidified, 5% CO 2 incubator. Next day, 10 ml/well of compounds were added (quadruplicate wells).
- ATCC American Type Culture Collection
- Collagen-1 ELISA assay After 72 hour incubation with the compound, supernatants were collected for Collagen-1 ELISA assay and cell viability was measured in a luminometer after the addition of 100 mL/well CellTiterGlo reagent (Promega Inc, Madison, WI) as recommended by the manufacturer.
- Collagen stimulating activity of immodulin peptides in HFF-1 dermal fibroblasts Peptides were added to cells at 2 uM.
- Collagen-1A1 (COL1) immunoreactivity was measured in the supernatants of cultured cells by ELISA using a rabbit monoclonal anti-COL1 primary antibody (Abcam, Cambridge, MA). The results of this experiment are shown in the Table below. Control (buffer) value of immunoreactivity was set to 100.
Abstract
Methods and compositions involving synthetic immodulin peptides and helper molecules. The peptides exhibit new and surprising biological activities, such as co-stimulation of macrophage and myogenic cell differentiation markers. Methods are provided N by which peptide is contacted with one or more myeloid precursor cell populations, thereby increasing the abundance of CD169+, CCL22+, Clec4A, Clec9a+, and Clec 12a+ monocyte lineages which play important roles in cross presentation, post-apoptotic clearance, autoimmunity, and programmatic tissue regeneration, notably in contexts of tissue stress, insult and degeneration. The disclosed methods and compositions enable concurrent regeneration of diverse cellular elements in tissue where collaborating myeloid and non-myeloid lineages are located together in a living tissue following the contacting steps. Furthermore, the peptides of the invention can be delivered with inherently specific in vivo targeting, achieved through complexation to holotransferrin and/or size-specific glycosaminoglycans (e.g. high-molecular- weight hyaluronan) so as to discriminate between target environments in vivo or ex vivo.
Description
- This application claims benefit of international application number PCT/US2021/046814, with an international filing date of 20 Aug. 2021, and international application number PCT/US2021/021433, with an international filing date of 9 Mar. 2021. PCT/US2021/046814 claims priority to international application number PCT/US2021/021433, which claims priority to international application number PCT/US2020/024828 with an international filing date of 26 Mar. 2020.
- This invention relates to the field of peptide therapeutics, and more particularly to the use of synthetic “immodulin” peptides (also optionally referred to as “immodulator peptides”) to selectively increase the abundance of two or more cooperating mammalian cell lineages in vivo or ex vivo. Cooperating lineages may include cells involved in the arbitration of inflammation (e.g. macrophages) followed, programmatically, by the regeneration of new cells in the same tissue. The compositions and methods provided herein demonstrate new and surprising uses of immodulin peptides for the regeneration of tissues in mammals.
- This invention provides synthetic immodulin peptides, originally derived from the sequences of classical insulin growth factor binding proteins (IGFBPs 1 through 6), and related compositions and methods. Insulin-like growth factors (IGFs) influence the growth and differentiation of mammalian cells. Unlike the full-length classical IGFBPs, whose primary function is to carry and deliver IGFs, the peptides of this invention are derived from less than 10% of the IGFBP amino acid sequence(s) and do not themselves bind IGFs. Thus, the effects of the synthetic immodulin peptides of this invention are unrelated to the effects of IGFs themselves. IGF-independent effects of classical IGFBPs have been known for decades, but there is no report of (IGF-independent) effects of IGFBP-derived peptides on monocyte differentiation, for example. Furthermore, tissue regeneration requires the coordinated action of multiple cell types. For example, certain myeloid lineages (notably macrophages specialized for anti-inflammatory and pro-efferocytotic functions) interact with tissue-resident precursor lineages for differentiation into roles vacated by cells that have recently succumbed to insult, such as ischemic, oxidative or inflammatory insult. It is a fundamental and central need in regenerative medicine to provide interventions that restore homeostasis to damaged, dysfunctional or degenerated tissue—such as by processing apoptotic cells efficiently through efferocytosis, restoration of mitochondrial integrity and resolution of inflammation by enhancing tolerization—while also providing appropriate stimulus for the differentiation of resident (and sometimes non-resident) precursor cells to take the place of departed cells. A holy grail in the field of regenerative medicine is the discovery of master regulatory molecules capable of conducting this type of programmatic cellular symphony. The synthetic immodulin peptides disclosed herein exhibit new and surprising biological effects on cellular differentiation, such as the stimulation of differentiated myeloid lineages that coordinate the disposal, re-programming and de novo differentiation of adult non-myeloid lineages from precursor cell populations in the tissue. For example, compositions and methods are disclosed herein for increasing the abundance of CD169+, CCL22+, and Clec12a+ cross-presenting myeloid lineages by contacting precursor cells in vivo or ex vivo with synthetic immodulin peptides, while also independently stimulating other, non-myeloid cell types in the tissue, such as myoblasts, to differentiate into complementary roles consistent with tissue regeneration and homeostasis. Such complementary myeloid and non-myeloid cell differentiation activities have never been disclosed for IGFBPs or for IGFBP-derived synthetic peptides. For example, in the over 7000 scientific papers published on IGFBP-3 and IGFBP-3-derived peptides in the past forty years, there is no disclosure of stimulation of differentiation of a specific monocytic or myogenic lineage using synthetic peptides derived from IGFBP-3 (or other classical IGFBP).
- The present invention describes the use of synthetic immodulin peptides to increase the abundance of mammalian cell lineages within a living animal or in a population of mammalian cells derived from an animal (i.e. in vivo or ex vivo). Importantly, the action of these peptides is IGF-independent, as these peptides do not bind IGFs. Cells treated with synthetic immodulin peptides ex vivo may subsequently be re-introduced into a living mammal. For example, hematopoietic or other mesenchymal cell lineages can be expanded so as to improve outcomes in cancer therapy, targeted vaccination, management of traumatic insults, anemia, neurodegeneration, regeneration of tissues, and prevention of medical complications from diseases such as obesity, diabetes, and diseases of aging.
- Synthetic immodulin peptides are believed to rapidly target and enter cells under stress, move to specific cellular compartments (e.g. the nucleus, cytoplasm, mitochondria), and interact with cellular machinery in different ways. For example, they can bind transcriptional factors and thereby alter large transcriptional sets.
- The use of short classical IGFBP-derived synthetic sequences to increase the abundance of differentiation markers in myeloid hematopoietic cell lineages (such as CD169+, CCL22+ or Clec12a+ monocytes, dendritic cells and macrophages) or in non-myeloid lineages important in re-establishment of tissue homeostasis (such as myoblasts, osteoblasts, chondroblasts, neuroblasts, fibroblasts and lymphocytes has never been disclosed. Indeed, to the inventor's knowledge, no other peptide molecule has ever been identified that is capable of such function. As tools for accomplishing targeted differentiation of mammalian cell precursors in vivo or ex vivo, the peptides of this invention are uniquely useful, for example, in the treatment of acute (driven by traumatic insult or myocardial infarction, for example) and chronic inflammatory skeletal myopathies, which have themselves been shown to trigger neurodegeneration, kidney disease, heart failure, COPD, and many of the degenerative conditions associated with aging. Numerous other applications secondary to reversing inflammatory loss of skeletal muscle will be readily apparent to skilled practitioners in the field.
- Retinoid X receptors (RXRα (NR2B1), RXRβ (NR2B2) and RXRγ (NR2B3)) are promiscuous heterodimeric partners for other members of the Nuclear Receptor (NR) superfamily including members of the NR1 group, which include thyroid receptors (TRs), retinoic acid receptors (RARs), peroxisome proliferator-activated receptors (PPARs), LXRs, FXR and many others; NR3 group (ERs, GR, MR, PR, AR); NR4 (notably NR4A1/Nur77); and members of other NR groups. RXRs are obligatory partners for a number of NR partners, placing RXRs in a coordinating role at the crossroads of multiple signaling pathways. RXRs represent important targets for pharmacologic interventions and therapeutic applications. RXRs function as master regulators producing diverse physiological effects through the activation of multiple nuclear receptor complexes. Immodulin peptides bind RXRs and Nur77 in vitro, and appear to guide heterodimer formation. RXR agonists alone, partner receptor agonists alone or a combination of both can activate dimers, including permissive heterodimers. Such complexes include those formed with PPARs such as PPARα, PPARβ PPARd PPARγ), FXR (farnesoid X receptor), LXR (liver X receptor), and the orphan NR4A group, including Nur77 and Nurr1. Nur77 and Nurr1 transcriptional activities can be indirectly manipulated through modulation of their heterodimeric partner RXR, using ligands such SR11237, BRF110, HX531 or HX600, or other RXR/NR4A ligands and modulators such as spironolactone, haloperidol, cytosporone B, C-DIM12, C-DIM8 and cilostazol; PPAR ligands such as fenofibrate, fenofibric acid, ciprofibrate, gemfibrozil, clofibric acid, elafibrinor, GW9578, RB394, MBX-8025, GW7647, ZLY032, GW590735, GW0742, GW501516 and Amorfrutin B; and NR ligands such as BMS195614, GW4064, BMS453, sobetirome, ciloflexor, TTNPB, adapalene and GW3965.
- Classical IGFBPs, from which the core sequences of the immodulin peptides of this invention are derived, are a highly conserved family of proteins, both structurally and functionally. The sequence of IGFBPs 3, 5 and 6 from which the peptides of this invention are derived are particularly closely conserved. These three IGFBPs form a major evolutionary Glade that diverged from IGFBPs 1, 2 and 4 more than 700 million years ago. Functional features present in the 3/5/6 Glade and not in the 1/2/4 Glade include metal binding, PIP2-binding and nuclear transport. Amino acid sequence identity in the C-terminal thyroglobulin type-1 domain from which the sequences of the immodulin peptides of this invention are derived, which is present in all classical IGFBPs, is higher within the 3/5/6 IGFBP Glade (for example, 59% between IGFBP-3 and -5, but only 31% between IGFBP-1 and -5). No synthetic immodulin peptide binds IGFs. Each immodulin sequence represents less than 10% of the original IGFBP sequence from which it derives. It would be surprising if an immodulin retained any of the biological activities of the IGFBP molecule, let alone allow prediction of which. The USPTO has explicitly acknowledged this fact by issuing numerous patent claims drawn to immodulin peptide sequences, even if the biological activities exemplified in those patents were also seen with the parent molecule, for example, metal-binding, or nuclear transport. (See U.S. Pat. Nos. 5,519,003/5,783,405/6,165,977/6,262,023/6,342,368/6,423,684/6,855,693/6,933,275/7,393,835/8,536,135/10,369,191). However, in this case, the inventor is not even aware of any prior disclosure wherein IGFBP proteins alone were successfully used to drive differentiation of mammalian monocyte, myogenic, osteogenic and lymphocytic lineages, and knows of no other peptide in biology that can do so. This is the first demonstration that short synthetic peptides containing less than 10% of an IGFBP sequence can trigger mammalian cell differentiation, notably in multiple cell types of critical importance to establishing tissue regeneration and homeostasis. The immodulin peptide -3, -5 and -6 core sequences of this invention are highly related and comprise, respectively:
-
SEQ ID NO: 1 GFYKKKQCRPSKGRKRGFCW SEQ ID NO: 2 GFYKRKQCKPSRGRKRGICW SEQ ID NO: 3 GFYRKRQCRSSQGORRGPCW - Successful use of synthetic peptides in medicine faces several practical obstacles relating to manufacture, targeted delivery and potency. The inventor has shown that selective use of D-amino acids at the C-terminal end of immodulin peptides helps both stability and potency. Furthermore, synthetic immodulin peptides of this invention are made additionally potent by covalent attachment to small molecules. Of dozens of small molecules tested, less than half gave industrially useful yields under the harsh conditions of conventional peptide synthesis. This is a surprising and unforeseen result. Moreover, the small molecules successfully used and disclosed herein had not, in most cases, been previously reported as adducts to other peptides. Thus, success in the creation of this new class of chemically modified peptides under industrially expedient manufacturing conditions is strictly trial-based.
- Novel features of immodulin peptides that aid in targeted delivery in a real-world context have significant implications in the translational success of this class of molecules in the marketplace. Immodulin peptides naturally bind iron and holotransferrin, a major iron-carrier in the circulation. This invention provides holotransferrin-bound immodulin peptide capable of discriminating phosphatidylinositol 4,5-bisphosphate (PIP2)-rich membrane domains. Immodulins 3/5/6 bind PIP2, which competes with transferrin for binding to peptides. Holotransferrin-bound immodulin 3 or 5 selectively binds high-molecular weight hyaluronan (HMW-HA) more strongly than low-molecular weight hyaluronan (LMW-HA), a key discriminant in selective delivery in vivo, as LMW-HA has been widely associated with inflammatory effects, whereas HMW-HA has been associated with anti-inflammatory effects of hyaluronan. Hyaluronan is an abundant glycosaminoglycan ubiquitously present in the extracellular matrix of cell targets. Even more surprisingly, low endocytic pH dramatically increases binding of holotransferrin-immodulin complex to HMW-HA, but not LMW-HA. Furthermore, the master receptor, CD44, a hyaluronan receptor associated with cellular architecture and differentiation, binds this holotransferrin-immodulin-HMW-HA trimeric complex in vitro. Coupled with the established and ubiquitous role of CD44 and of a recently described endocytic nuclear iron-glycan uptake pathway that is CD44-associated, the intrinsic nuclear translocation and iron-binding properties of immodulins may provide a mechanistic link to the profound influences exerted by immodulins in the context of tissue regeneration. The synthetic peptides of the present invention thus benefit from selective carriage to target cells (such as mesenchymal cells under stress, as shown in references provided), selective uptake by receptors located in favorable membrane domains (such as PIP2-rich domains), selective transfer to a glycan carrier under the low pH conditions of an endocytic environment (such as HMW-HA and HMW-HA::CD44 complex), efficient nuclear import (using the nuclear import sequence contained in the immodulin peptides, as detailed in th references), and the ability to access chromatin wherein RXRs can control transcriptional programs (by stimulation of binding in heterodimeric complexes with NR partners, or by modification of kinase or HDAC activity, for example, as shown in priority documents and in this document).
- This invention discloses new compositions and new or improved utilities for the immodulin peptide class. Sequence extensions to immodulin core sequences disclosed in the invention confer new biological activities useful in treating human disease and in cosmetics. Previously known utilities of immodulin peptides are described, for example, in PCT/US2020/024828, PCT/US2021/021433, PCT/US2021/046814, U.S. Pat. Nos. 5,519,003/5,783,405/6,165,977/6,262,023/6,342,368/6,423,684/6,855,693/6,933,275/7,393,835/8,536,135/10,369,1919; and references cited therein. These are all hereby incorporated by reference.
- Methods disclosed in this invention include the administration of pharmaceutical compositions containing immodulin peptides to a mammal showing symptoms that may be linked to disease conditions, including but not limited to metabolic, muscle-wasting, neurodegenerative and cardiovascular diseases (especially those characterized by some underlying combination of insulin resistance, hyperglycemia, hypertension or hyperlipidemia); immune response to targeted vaccination, cancer progression and metastasis, pulmonary distress and acute kidney injury (AKI) in critical care settings, sepsis, anemia, systemic inflammatory conditions such as shock, post-operative oxidative stress such as after cardiopulmonary bypass or transplant, burns, blunt trauma, pancreatitis, rhabdomyolysis, xenobiotic stresses caused by cocaine, nicotine, alcohol, aminoglycoside antibiotics, cyclosporins, antiviral compounds or chemotherapeutic agents such as platinum compounds or doxorubicin; neuropathic pain and migraine; neurodegenerative diseases such as major depression, Parkinson's, Alzheimer's, Huntington's and ALS/Lou Gehrig's disease; immunosuppression phenomena; chronic obstructive pulmonary disease and other pulmonary diseases; pathological angiogenesis; impaired wound healing; ototoxicities; autoimmune conditions such as lupus erythematosus, arthritis, psoriasis, colitis, fibromyalgia, and multiple sclerosis; genetic diseases such as immune insufficiencies; cystinosis, Fanconi's and other conditions affecting mitochondrial respiration; other forms of mitochondrial dysfunction of bioenergetic failure; pulmonary diseases, especially chronic obstructive pulmonary disease, pulmonary arterial hypertension and asthma; ocular diseases such as cataracts and retinopathies, and conditions caused by infectious agents, including chronic viral infections such as hepatitis, influenza and coronavirus.
- In one aspect, the invention provides a synthetic peptide, 20-60 amino acids in length, comprising: (i) a core immodulin sequence corresponding to any one of SEQ ID NOs:1-6; and, optionally, (ii) a small molecule of molecular mass less than one thousand daltons linked covalently to the amino terminus of the peptide. In some embodiments the small molecule is selected from the group consisting of: oleic acid, lauric acid, 2-hydroxy-2-decenoic acid, phenolic acids, anthraquinones, pentacyclic triterpenoids, retinoic acids, bexarotene and other rexinoids, rhein, proprionic acids, TLR4 inhibitors, keto acids, cinnamic acids, aromatic carboxylic acids, indoleacetic acids, xanthenes, xanthones, 2,7-dichlorodihydro-fluorescein diacetate, indolyl-carboxylic acids, PF-06409577, AICAR, D942, PT1, EX-229, GIT27, GW501516, GW3965, GW9578, RB394, MBX-8025, GW7647, ZLY032, GW590735, GW0742, Amorfrutin B, BMS195614, GW4064, BMS453, FTY720, artesunate, artemisinic acid, sobetirone, cilofexor, decanoic acid, eicosapentaenoic acid, docosahexanoic acid, lignoceric acid, TTNPB, adapalene, bexarotene, transcinnamic acid, fenofibric acid, ciprofibrate, chlorfibric acid, gemfibrozil, elafibrinor, pioglitazone, roziglitazone, valproic acid, 2-hexyl-4-pentynoic acid, ibuprofen, C646, SR11237, MSA-2, SR-717 and bromopyruvic acid.
- In some embodiments a synthetic immodulin peptide is complexed or co-administered with a metal selected from the group consisting of: ferrous iron, ferric iron, zinc, copper, ruthenium, cobalt, titanium and calcium.
- In some embodiments a synthetic immodulin peptide described herein is complexed or co-administered with a glycosaminoglycan or other extracellular matrix component including a group consisting of: collagen, transferrins, other iron-binding proteins, heparin, heparan sulfate, chondroitin sulfate, keratan sulfate, dermatan sulfate, and hyaluronate.
- In some embodiments a synthetic immodulin peptide described herein is co-administered with a helper molecule selected from a group consisting of: phytochemicals, ornithine, leucine, raffinose sugar, trehalose sugar, avocado sugar, lactate, bile salts, cyclodextrin, resveratrol, polydatin, ursolic acid and cyclic dinucleotides.
- In a related aspect, the invention provides a pharmaceutical composition that includes any synthetic immodulin peptide or peptide complex described herein, and a pharmaceutically acceptable excipient.
- In yet another related aspect the invention provides a method for treating a subject suffering from immunological, neurological, myopathic, oncologic, skeletal, reproductive, metabolic or cosmetic dysfunction or imbalance, where the method includes administering to the subject (e.g., a human subject) a therapeutically effective dose of a synthetic immodulin peptide or immodulin peptide/helper molecule complex, or a pharmaceutical composition as described herein. In some embodiments the therapeutically effective dose of the synthetic immodulin peptide is from about 0.01 mg/kg/day to about 50 mg/kg/day.
- In yet another related aspect, the invention provides an in vitro method for using cultured mammalian cells to measure the potency of any immodulin peptide described herein.
- The compositions of the invention may be administered by means that include but are not limited to intravenous, oral, subcutaneous, intraarterial, intramuscular, intracardial, intraspinal, intrathoracic, intraperitoneal, sublingual, transdermal, intranasal and by inhalation.
- The terms “subject” and “individual”, as used herein, refer to mammalian individuals, and more particularly to pet animals (e.g., dogs, cats), agricultural animals (e.g., cows, horses, sheep, and the like), and primates (e.g., humans).
- The term “treatment” is used herein as equivalent to the term “alleviating”, which, as used herein, refers to an improvement, lessening, stabilization, or diminution of a symptom of a disease or immune imbalance. “Alleviating” also includes slowing or halting progression of a symptom.
- As used herein, “co-administration”, “in conjunction with”, “concurrent”, or “concurrently”, as used interchangeably herein, refers to administration of one treatment modality in addition to another treatment modality. As such, “in conjunction with” refers to administration of one treatment modality just before, during or soon after delivery of the other treatment modality to the subject.
- The term “synthetic immodulin peptide” shall mean a peptide molecule 20-60 amino acids in length prepared by chemical synthesis and comprising any of SEQ ID NOs:1-6.
- The term “phytochemical” shall include D-heptomannulose, trehalose, naringin, resveratrol, polydatin, plumbagin, quercetin, curcumin, berberine, alpha-mangostin, wogonin, and ursolic acid.
- The term “rexinoid” includes all ligands of RXRs, and conjugates thereof.
- The term “bexarotene-class rexinoid” shall include bexarotene, LG100268, SR11237, HX600, HX531, BRF110 and conjugates thereof.
- The term NSAID includes ibuprofen, sulindac (and its sulfide and sulfone derivatives), indomethacin, aspirin, naproxin, ketoprofen, ketorolac, diclofenac and etodolac, and conjugates thereof.
- The term “RLR/STING/IFN-class agonist” shall include cyclic dinucleotides such as 2′3′cGAMP and cyclic di-GMP, nucleotides such poly-I:C and double-stranded ppp-RNA, and small molecule agonists such as G10, KIN1400, KIN1408, KIN 1148, R08191, MSA-2, SR-717, alpha-mangostin, DMXAA and conjugates thereof.
- The term “NR4A-class ligand” shall include spironolactone, haloperidol, cytosporone B, C-DIMS, C-DIM8, C-DIM12, cilostazol, PDNPA and conjugates thereof.
- The term “immunomodulant-class molecule” shall include GIT-27, Schisandrin A, resiquimod (R-848), hydroxychloroquine, pidotimod, itraconazole, homoharringtonine, salidroside, celastrol, zymostenol, 7-dehydrocholesterol and conjugates thereof.
- The term “Wnt-class molecule” shall include gallic acid, methyl gallate, gallocyanine, epigallocatechin gallate, XAV939, ethacrynic acid, leonurine and conjugates thereof.
- “Significantly increasing the abundance of a mammalian cell lineage differentiation marker” shall mean increasing the relative average abundance of the cell lineage differentiation marker in the population of cells contacted with synthetic immodulin peptide by at least fifteen percent over an untreated population control, such that the average difference between the two populations is statistically significant—for example, with a calculated probability of p<0.05 using Student's T-test, or other comparable statistical test, well known to those skilled in the art. “Differentiated mammalian cell lineage” means a living mammalian cell population expressing markers and/or functions characteristic of a differentiated cell type. “In vivo” treatment means treatment within a living animal. “Ex vivo” treatment means treatment of a mammalian cell population after its removal from an animal. Ex vivo-treated cells may optionally be re-introduced into the animal. “Precursor cell”, in the context of the invention, means a living mammalian cell capable of cellular differentiation. Quantitation of a marker can be made using commercially available kits for such a marker. The kits may measure different aspects of such a marker, such as gene expression, protein abundance, protein activity and biochemical or clinical consequences thereof.
- “Significantly altering the relative abundance or bioactivity of a marker” means changing the average abundance or biological activity of a protein, mRNA, carbohydrate, lipid, metabolite or other biological analyte whose changed abundance or bioactivity is measurable in a population of cells by practitioners skilled in the art using commercially available kits, wherein the change is shown to occur to a statistically significant degree in cells treated by the methods of this invention compared to a control population. The difference between average measured abundance or bioactivity of a marker is significantly different in a population of cells that received treatment by the methods of this invention (as compared to an untreated control population of cells) if the difference between the two populations is statistically significant, for example, with a calculated probability of p<0.05 using Student's T-test, or other comparable statistical test well known in the art. The abundance or bioactivity of a marker, such as a protein or RNA known to be diagnostic for the differentiated cell population in question, can be readily measured using commercially available test kits, well-known and widely used in the field e.g. ELISA kits, qPCR kits, enzymatic activity kits, etc. Test kits can be purchased for cell surface markers such as CD169, Clec9a, Clec10a, Clec12a, CD205, CD207, CD209, CD209L and MHCII, secreted proteins such as IL-10, TGFbeta, TNFalpha, CCL22 and COL1A1 (collagen), and nuclear proteins such as FoxP3, Nur77/NR4A1, RXRs, PPARs and other modulators of transcrition.
- “RXR” means retinoid X receptor, and can refer to either the RXR gene or the protein it specifies. “Rexinoid” means a ligand of an RXR receptor. “RXRs” means any of the RXR isoforms, such as RXR-alpha, RXR-beta, RXR-gamma, and also covers heterodimers formed between them and other nuclear receptors such as NR4As. “NR4As” includes the orphan nuclear receptors NR4A1, NR4A2 and NR4A3, and can refer to either the NR4A gene or the protein it specifies. RXR receptors can and do form functional heterodimers with a variety of other nuclear receptors such as retinoic acid receptors (RARs), thyroid receptors (TRs), vitamin D receptor (VDR), liver X receptors (LXRs), peroxisome proliferator-activated receptors (PPARs), and the aforementioned NR4As.
- “CD169” (also known as Siglec-1) means sialoadhesin, a cell adhesion molecule found on the surface of macrophages. Orthologs of this molecule in other mammalian species are included in this definition.
- “C-lectins” means a C-type lectin such as Clec4a, Clec9a, Clec10a or Clec12a, and orthologs thereof.
- “CCL22” (also known as MDC) means C-C motif chemokine 22, and its orthologs.
- “COL1A1” means alpha-1 Type I collagen.
- “STING” means “stimulator of interferon genes. STING is also known as TMEM173.
- “Nur77” is the protein product of the NR4A1 gene. As an analyte, the two terms are here used interchangeably. Sometimes the gene product may be referred to as Nur77/NR4A1 or NR4A1/Nur77.
- This invention provides a method for stimulating levels of differentiation markers in myeloid and non-myeloid mammalian cell lineages in vivo or ex vivo, the method comprising: (i) contacting one or more mammalian cells of a myeloid lineage with a synthetic immodulin peptide about 20 to about 60 amino acids in length and comprising an amino acid sequence corresponding to any one of SEQ ID NOs:1-6; and (ii) contacting one or more mammalian cells of a non-myeloid lineage with said synthetic immodulin peptide; and (iii) measuring a readout of differentiation for the myeloid mammalian cell lineage wherein said readout is accompanied by a significantly increased average level of at least one marker for myeloid lineage differentiation in the contacted cells of the myeloid lineage; and (iv) measuring a readout of differentiation for the non-myeloid mammalian cell lineage wherein said readout is accompanied by a significantly increased average level of at least one marker for non-myeloid lineage differentiation in the contacted cells of the non-myeloid lineage; wherein the at least one marker for myeloid lineage differentiation is CD169, CCL22, Clec4A, Clec9a, Clec10a or Clec12a, and wherein cells of said myeloid and non-myeloid lineages following the contacting steps are co-resident in a living tissue. Under the method, cells of said myeloid and non-myeloid lineages following the contacting steps may come to be co-resident in a living tissue by contacting the synthetic immodulin peptide to each lineage separately or concurrently, wherein “concurrently” shall mean simultaneously, at approximately the same time, or in immediate or overlapping sequence, and having any of the contacting steps take place either in vivo or ex vivo.
- Non-myeloid lineages may include cells of a neurogenic lineage, wherein the readout is neurogenesis, and the marker for differentiation is selected from the group consisting of: synaptophysin, synaptopodin, vimentin, NMDAR, AChR, and PSD95. Non-myeloid lineages may also include cells of a myogenic lineage, wherein the readout is myogenesis, and the marker for differentiation is selected from the group consisting of: creatine kinase, myogenin, MYF-4, MYF-5 and actinin-2. Myogenesis includes formation of myotubes as well as higher order structures. Non-myeloid lineages may also include cells of an osteogenic lineage, wherein the readout is osteogenesis, and the marker for differentiation is selected from the group consisting of: alkaline phosphatase, calcified deposits, osteocalcin and BMP-2. Non-myeloid lineages may also include cells of a chondrogenic lineage, wherein the readout is chondrogenesis, and the marker for differentiation is selected from the group consisting of: type II collagen, aggrecan and Sox 9. Non-myeloid lineages may also include cells of a keratinocytic lineage, wherein the readout is differentiated keratinocytes and the marker of differentiation is selected from the group consisting of keratin-10, profilaggrin, loricrin and involucrin. Non-myeloid lineages may also include cells of a lymphocytic lineage, wherein the readout is differentiated lymphocytes and the marker of differentiation is selected from the group consisting of FoxP3 and IL-10. Non-myeloid lineages may also include cells of a pulmonary lineage, wherein the readout is differentiated pulmonary cells and the marker of differentiation is selected from the group consisting of NKX2.1, HOPX, GPRC5A, AGER or AQP5. Non-myeloid lineages may also include cells of a fibroblastic lineage, wherein the readout is differentiated fibroblasts and the marker of differentiation is COL1A1. Non-myeloid lineages may also include cells of a nephrogenic lineage, wherein the readout is differentiated kidney cells and the marker of differentiation is selected from the group consisting of CALB1, AQP2, AVPR2 and PENDRIN. Non-myeloid lineages may also include cells of a hepatogenic lineage, wherein the readout is differentiated liver cells and the marker of differentiation is selected from the group consisting of AAT1, alpha-fetoprotein, HNF-4a, glycogen and albumin.
- This invention provides for measuring a readout of differentiation for the non-myeloid mammalian cell lineage. A “readout” may refer to a gene readout (for example, gene transcription), a protein readout (for example by ELISA, or enzymatic assay), a biochemical readout (for example, by assay of a molecule that is not a nucleic acid, peptide or protein) or a functional readout (for example by clinical readout of a patient's symptoms). Transcription can be quantitated in mammalian cells or tissues by techniques such as quantitative PCR (qPCR). Commercially available kits can measure levels of analytes, both protein and non-protein. A clinician's expertise facilitates assessment of a patient's symptoms. For examples, changes in grip strength can be measured with a dynamometer. Body temperature may be measured using a thermometer.
- This invention also provides a peptide having an amino terminus formed by covalent linkage to a “small molecule” of molecular mass less than one thousand daltons, preferably less than five hundred daltons. Said “small molecule” is selected from the group consisting of PF-06409577, AICAR, D942, PT1, EX-229, GIT27, GW501516, GW3965, GW9578, RB394, MBX-8025, GW7647, ZLY032, GW590735, GW0742, Amorfrutin B, BMS195614, GW4064, BMS453, FTY720, artesunate, sobetirone, cilofexor, decanoic acid, eicosapentaenoic acid, docosahexanoic acid, lignoceric acid, TTNPB, adapalene, bexarotene, transcinnamic acid, fenofibric acid, ciprofibrate, chlorfibric acid, gemfibrozil, elafibrinor, pioglitazone, roziglitazone, valproic acid, 2-hexyl-4-pentynoic acid, and ibuprofen.
- The invention also provides a synthetic immodulin peptide comprising a core sequence selected from the group consisting of any of SEQ ID NOs: 1-6. In some embodiments, said core sequence is aminoterminally extended by a sequence comprising any of sequence ID NOs: 7-14.
- In some embodiments the invention provides kinase modulating sequences to be used in conjunction with the immodulin sequences of this invention. Kinase inhibitor peptides have been widely used by practitioners in the field for several decades. For example, U.S. Pat. No. 5,783,405 lists dozens of peptide sequences and teaches their use as protein kinase C inhibitors. Among them are the sequences AFNSYELGS and SLNPEWNET, claimed to inhibit PKC-delta and PKC-beta, respectively, as well as PKC-epsilon stimulating sequences such as NGLLKIK.
- In some embodiments the invention provides a synthetic immodulin peptide in a complex with non-covalently bound, purified holotransferrin at about 0.1 to about 10 molar equivalents of one to the other. Holotransferrin is transferrin in which at least one of the iron-binding sites is occupied by ferric iron. The peptide-holotransferrin binary complex provides better targeting of the synthetic immodulin peptide in vivo by virtue of its preferential binding to high-molecular weight size classes of glycosaminoglycans, notably hyaluronan (HMW-HA) which are, in turn, taken up by the receptor CD44 in preferred contexts. The terms “hyaluronan” and “hyaluronic acid” are herein used interchangeably. In some aspects, preferential binding of the binary complex to PIP2, which is enriched in preferred cellular membrane contexts for resolution of inflammation and cellular differentiation, may also (and independently) increase specificity of targeting in vivo.
- In some embodiments the invention provides a synthetic immodulin peptide in a complex with non-covalently bound, purified holotransferrin at about 0.1 to about 10 molar equivalents of one to the other, additionally complexed to HMW-HA at about 0.01 to about 100 molar equivalents of purified high-molecular weight hyaluronan relative to peptide. In some aspects, the stability of this ternary complex is stronger at pH 5.2 (endocytic pH) than at pH 7.4, the physiological pH in most cellular compartments. In some aspects, the stability of this ternary complex containing HMW-HA is stronger than the corresponding ternary complex containing LMW-HA. Size classes of hyaluronan are thought to play key roles in inflammation. In some embodiments the invention provides compositions comprising said ternary complex.
- In another aspect, the invention provides a method for treating a mammal showing symptoms of immune dysfunction or imbalance comprising administering to said mammal via intramuscular, subcutaneous, parenteral, transdermal, intranasal, intravenous or intrathecal route of administration a pharmaceutical formulation comprising a therapeutically effective dose of an immodulin peptide according to the invention, and a pharmaceutically acceptable excipient, thereby alleviating said symptoms of dysfunction. In some embodiments, the immodulin peptide is administered in a therapeutically effective dose of peptide between about 0.01 mg/kg/day to about 50 mg/kg/day.
- In another aspect, the invention provides for co-administration of a helper molecule selected from a group consisting of: ornithine, leucine, raffinose, trehalose, resveratrol, polydatin, ursolic acid, lactate, bile salt, metal, cyclodextrin and cyclic dinucleotide.
- This invention envisages an in vitro method for measuring cell differentiating potency of a synthetic immodulin peptide, the method comprising measurement of the abundance of a marker selected from the group consisting of PPARs, RXRs, NR4As, CD169, CCL22, IL-10, TGFbeta, FoxP3, C-lectins, COL1A1, TNFalpha, NfkappaB, MMP-9, IL-6, STING, interferons, RLRs or toll-like receptors in cultured mammalian cells that have been treated with the synthetic peptide. As will be understood by those of skill in the art, the mode of detection of a diagnostic signal will depend on the detection system utilized in the assay. For example, if a fluorescent detection reagent is utilized, the signal may be measured using a fluorometer. If a chemiluminescent detection system is used, then the signal can be detected using a luminometer. Either gene expression (via qPCR) or protein levels and/or enzymatic activity may be measured. Methods for detecting signal from detection systems for such analytes are well known in the art and need not be further described here.
- Sequence “identity” and “homology”, as referred to herein, can be determined using BLAST, particularly BLASTp as implemented by the National Center for Biotechnology Information (NCBI), using default parameters. It will be readily apparent to a practitioner skilled in the art that sequences claimed hereunder include all homologous and trivial variants of an immodulin peptide, such as by conservative substitution, extension and deletion in amino acid sequence. Trivial substitution variants include swapping of an amino acid with another belonging to the same class, without such substitution resulting in statistically and functionally significant change. “Classes” of amino acids include positively charged amino acids (arginine, lysine, histidine), negatively charged amino acids (aspartic acid, glutamic acid), aromatic amino acids (tyrosine, phenylalanine, tryptophan), branched chain amino acids (valine, leucine isoleucine) and other natural groupings such as (serine, threonine) and (asparagine, glutamine). For the purposes of this invention, such conservative substitutions to immodulin sequences, if they do not create a significant change in function, are considered equivalent to the original and are covered by the scope of this invention.
- For testing efficacy of pharmaceutical composition containing an immodulin peptide, an effective amount of therapeutic agent is administered to a subject having a disease. In some embodiments, the agent is administered at about to about 50 milligrams per kilogram total body weight per day (mg/kg/day). In some embodiments the agent is administered at about 0.001 to about 50 mg/kg/day, e.g., 0.01, 0.015, 0.02, 0.05, 0.1, 0.2, 0.5, 0.7, 1, 2, 4, 5, 7, 9, 10, 15, 25, 30, 35 or another dose from about 0.001 mg/kg/day to about 50 mg/kg/day.
- Therapeutic agents are preferably administered via oral or parenteral administration, including but not limited to intravenous (IV), intra-arterial (IA), intraperitoneal (IP), intramuscular (IM), intracardial, subcutaneous (SC), intrathoracic, intraspinal, intradermal (ID), transdermal, oral, sublingual, inhaled, and intranasal routes. IV, IP, IM, and ID administration may be by bolus or infusion administration. For SC administration, administration may be by bolus, infusion, or by implantable device, such as an implantable minipump (e.g., osmotic or mechanical minipump) or slow release implant. The agent may also be delivered in a slow release formulation adapted for IV, IP, IM, ID or SC administration. Inhaled agent is preferably delivered in discrete doses (e.g., via a metered dose inhaler adapted for protein delivery). Administration of a molecule comprising an agent via the transdermal route may be continuous or pulsatile. Administration of agents may also occur orally. For parenteral administration, compositions comprising a therapeutic agent may be in dry powder, semi-solid or liquid formulations. For parenteral administration by routes other than inhalation, the composition comprising an agent is preferably administered in a liquid formulation. Compositions comprising an agent formulation may contain additional components such as salts, buffers, bulking agents, osmolytes, antioxidants, detergents, surfactants, and other pharmaceutical excipients as are known in the art.
- As will be understood by practitioners skilled in the art, the symptoms of disease alleviated by the instant methods, as well as the methods used to measure the symptom(s) will vary, depending on the particular disease and the individual patient. All references cited in this document, including patent applications and publications cited therein, are incorporated by reference in their entirety.
- N-terminally biotinylated versions of the peptides listed below were used in various assays listed in the examples. For the two types of phosphatidylinositon phosphate (PIP)-binding assays, imm1-imm6 peptides were used.
-
PEPTIDE SEQUENCE None (buffer) imm1 KNGFYHSRQCETSMDGEAGLCW imm2 KHGLYNLKQCKMSLNGQRGECW imm3 KKGFYKKKQCRPSKGRKRGFCW imm4 RNGNFHPKQCHPALDGQRGKCW imm5 RKGFYKRKQCKPSRGRKRGICW imm6 HRGFYRKRQCRSSQGQRRGPCW immX3AVD KKGFYKKKQCRPSKGRKRGFCWAVD immX4AVD RNGNFHPKQCHPALDGQRGKCWAVD immX5AVD RKGFYKRKQCKPSRGRKRGICWAVD immX3dAVD KKGFYKKKQCRPSKGRKRGFCW(dA)VD immX3dAdVdD KKGFYKKKQCRPSKGRKRGFCW(dA)(dV)(dD) immX3dSdVdD KKGFYKKKQCRPSKGRKRGFCW(dS)(dV)(dD) immX3K4e+1 NGLLKIKKGFYKKKQCRPSKGRKRGFCWAVD immX3K4e+2 HDAPIGYDKKGFYKKKQCRPSKGRKRGFCWAVD immX3K4edSdVdD NGLLKIKKGFYKKKQCRPSKGRKRGFCW(dS)(dV)(dD) immX3K1dAdVdD SLNPEWNETKGFYKKKQCRPSKGRKRGFCW(dA)(dV)(dD) Underlined residues are D-amino acids - In the PIP-binding membrane assay, 400 ng of each peptide was bound to Membrane Lipid Strips (Catalog # P-6002, Echelon Biosciences, Salt Lake City, UT) and developed according to the manufacturer's instructions. Binding to PIPs was as follows (−−− no binding; +++ strong binding):
-
PtdIns(4)P PtdIns(4,5)P PtdIns(3,4,5)P PEPTIDE Phosphatidylinositol [PIP1] [PIP2] [PIP3] imm1 — — — — imm2 — — — — imm3 — — +++ ++ imm4 — — — — imm5 — ++ +++ ++ imm6 — — + — - In the plate assay, biotinylated peptides imm3 and imm5 were bound to 96-well, streptavidin-coated plates (BioLegend corporaton, San Diego, CA) at 400 ng per well in PBS buffer at room temperature for 60 mins. Plates were washed in PBS and developed with FITC-labelled PIP2 (purchased from Cayman Chemical Co, Ann Arbor, MI). Fluorescence was counted in a laboratory fluorescence spectrophotometer. The results were as follows (EDTA background set to =100; **p<0.01 vs background control):
-
Background PEPTIDE Control Zinc Ferric Iron imm3 1.0 ± 0.8 4.7 ± 1.3** 26.2 ± 5.7** imm5 1.8 ± 0.5 5.0 ± 1.2** 23.4 ± 3.5** - Mammalian cell differentiation assays employed the THP1-Dual monocyte reporter cell line (Invivogen Inc, San Diego, CA) seeded at 2×10e5 cells per well in 96-well plates and cultured at 37 degrees C. in RPMI-1640 growth medium plus 10% fetal bovine serum and 1% penicillin/streptomycin. Cells were subsequently treated for 24 hours with 100 ng/ml Phorbol 12-myristate 13-acetate (PMA protocol; Cayman Chemical Company, Ann Arbor, MI). Peptide (0.33 uM or 0.66 uM, as indicated) was then added, and incubation continued for an additional 24 hours. Culture supernatants were assayed for CCL22. Plates with adherent cells were washed with PBS and assayed for immunoreactivity of surface markers such as CD169, Clec9a or Clec12a using fuorescent tag- or biotin-labeled anti-human antibodies purchased from Miltenyi Biotec (Auburn, CA) and the secondary detection reagent recommended by the manufacturer. Results were expressed as arbitrary units relative to the control immX3AVD peptide, and p values were also calculated and shown relative to the control immX3AVD peptide (values significantly above background are shown in bold font; **p<0.05 versus immX3AVD control; AU=arbitrary immunoreactivity units relative to control, avg±SD).
-
PEPTIDE CD169+ (AU) CCL22 pg/ml Clec12A(AU) None (buffer) 1.2 ± 1.1** 17.1 ± 1.2** 0.5 ± 3.2** imm1 3.1 ± 2.2** n.d. n.d. imm2 3.0 ± 0.5** n.d. n.d. imm3 27.8 ± 3.0** 55.3 ± 16.1** n.d. imm4 3.8 ± 1.1** n.d. n.d. imm5 36.5 ± 3.0** n.d. n.d. imm6 19.9 ± 2.3** n.d. n.d. immX3AVD 100 282.4 ± 18.4 100 immX4AVD 1.0 ± 0.3** n.d. n.d. immX5AVD 100.9 ± 3.5 228.6 ± 8.1 n.d. immX3dAVD 104.3 ± 6.1 247.3 ± 16.1 n.d. immX3dAdVdD 183.3 ± 6.4** n.d. 106.6 ± 5.2 immX3dSdVdD 145.7 ± 9.3** n.d. n.d. immX3FVS 109.4 ± 4.5 251.3 ± 5.8 n.d. immX3RVD 88.1 ± 4.2 272.5 ± 35.7 n.d. immX3K4e + 1 128.4 ± 1.4** n.d n.d immX3K1dAdVdD 249.3 ± 13.9** 135.8 ± 24.2** 321.9 ± 25.6** AU: arbitrary units (immunoreactivity); #: PMA protocol; ## cytokine protocol; n.d. = not determined - The THP1-Dual cell differentiation assay was carried out as described above in Example 2, using immX3 peptide (330 nM) in all samples plus the indicated helper or inhibitor molecule. Molecules were purched from Cayman Chemical Company (Ann Arbor, MI) or Sigma Chemical Company (St. Louis, MO). AU=arbitrary ELISA units. **p<0.01.
-
HELPER CAS# CLASS [CONC] CD169 (AU) None (buffer) 100.0 ± 4.9 Holotransferrin (Tf) Fe-binding protein 0.8 ug/ml 126.8 ± 9.3** Hyaluronan(HMW-HA) glycosaminoglycan 0.6 ug/ml 110.5 ± 10.2 HMW-HA + Tf 2.0 ug/ml # 82.1 ± 7.5** LMW-HA + Tf 2.0 ug/ml # 120.6 ± 7.8 Heparin glycosaminoglycan 1.0 ug/ml 34.1 ± 2.9** Supercinnamaldehyde 70351-51-8 C/EBPb inhibitor 2 uM 159.7 ± 16.6** Bisindolylamide 138489-18-6 PKC inhibitor 2 uM 130.1 ± 8.4** RIG-I agonist [a] RIG-I agonist 1 ug/ml 135.4 ± 9.1** G10 702662-50-8 STING agonist 2 uM 143.4 ± 17.8** 2′3′-cGAMP Cyclic dinucleotide 15 uM 168.5 ± 10.9** Cyclic-di-GMP Cyclic dinucleotide 15 uM 142.9 ± 9.7** D-mannoheptulose Sugar 50 uM 140.8 ± 12.4** D-raffinose Sugar 1 mM 111.9 ± 4.0** L-lactate Acid 300 uM 121.1 ± 5.6** L-fumarate Acid 1 mM 101.5 ± 7.3 HP-B-cyclodextrin Starch 1 mM 121.1 ± 4.6** Calcitriol 32222-06-3 VDR agonist 2 uM 102.0 ± 11.3 Spironolactone 52-01-7 RXR or NR4A ligand 2 uM 120.1 ± 10.5** C-DIM12 178946-89-9 RXR or NR4A ligand 2 uM 119.0 ± 3.7** C-DIM8 151358-47-3 RXR or NR4A ligand 2 uM 91.0 ± 24.8 Clobetasol 25122-46-7 RXR or NR4A ligand 2 uM 98.5 ± 5.5 Cilostazol 73963-72-1 RXR or NR4A ligand 2 uM 99.4 ± 27.7 Cytosporone B 321661-62-5 RXR or NR4A ligand 2 uM 120.3 ± 6.4** Dihydroergotamine 6190-39-2 RXR or NR4A ligand 2 uM 170.3 ± 20.7** 6-mercaptopurine 6112-76-1 RXR or NR4A ligand 2 uM 104.9 ± 4.0 Bexarotene 153559-49-0 RXR or NR4A ligand 2 uM 96.9 ± 6.8 LG100268 153559-76-3 RXR or NR4A ligand 2 uM 76.8 ± 11.9** HX600 172705-89-4 RXR or NR4A ligand 2 uM 110.5 ± 19.0 HX531 188844-34-0 RXR or NR4A ligand 2 uM 90.4 ± 6.2 Cyclosporine A NFAT inhibitor 2 uM 128.9 ± 6.7** GM-CSF Growth factor class 0.1 ug/ml 147.0 ± 15.3** CSF1 Growth factor class 0.1 ug/ml 108.0 ± 32.3 Leptin Growth factor class 1.0 ug/ml 103.3 ± 11.6 GIT27 6501-72-0 TLR4 inhibitor 2 uM 166.5 ± 34.1** [a] Invivogen Inc. (San Diego, CA) Cat.# tlrl-3prnalv; # each helper at 2 ug/ml; - Effects of pH, PIP2 and size classes: Streptavidin-coated 96-well plates (G-Biosciences, St. Louis, MO) were pre-loaded with biotinylated peptides [see Example 1] at 400 ng/well, at room temperature for 60 minutes. The plate was washed with PBS buffer and then 1 ug FITC-labelled heparin or hyaluronic acid (FITC-HMW-HA) in 100 uL PBS buffer was added per well (all tests done in quadruplicate). Incubation proceeded for 90 minutes at room temperature, followed by two PBS washes. The plate was read in a standard laboratory fluorometer (488/525 nm exitation/absorbance) and the counts normalized for immX3 peptide binding=100. Values statistically above background are shown in bold font. **p<0.05 versus immX3AVD.
-
PEPTIDE Heparin Hyaluronate imm2 27.4 ± 22.9 3.1 ± 9.8 imm3 104.2 ± 22.0 57.2 ± 5.7** imm4 6.8 ± 24.1 14.6 ± 22.6 imm5 95.1 ± 25.7 60.0 ± 8.6** imm6 97.2 ± 17.3 44.9 ± 14.1** immX3AVD 100.0 ± 4.7 100.0 ± 22.8 immX4AVD 7.3 ± 17.1 61.1 ± 34.1 immX5AVD 68.7 ± 26.2 113.9 ± 15.7 immX3dAdVdD 55.5 ± 5.7** 104.2 ± 14.7 immX3K1dAdVdD 56.0 ± 7.3** 101.9 ± 16.4 - A second binding experiment was done as above, but using either 6 mM sodium phosphate buffer pH 7.4 or sodium citrate buffer pH 5.2 in the presence of FITC-HMW-HA (1.5 ug/well), holotransferrin (10 ug/well) and excess PIP2 (500 ng/well), LMW-HA (hexamer; 10 ug/well) or HMW-HA (10 ug/well). **p<0.05 versus peptide binding control (=100);
-
pH Peptide CONTROL +cold PIP2 +cold LMW-HA +cold HMW-HA 7.4 None (buffer) 4.3 ± 3.8** n.d. n.d. n.d. 7.4 immX3AVD 100.0 ± 8.3 10.4 ± 8.2** 92.6 ± 11.8** 18.5 ± 3.7** 7.4 immX5AVD 100.0 ± 7.6 53.7 ± 2.1** 94.9 ± 11.4 22.6 ± 8.8** 5.2 None (buffer) 27.3 ± 8.4** n.d. n.d. n.d 5.2 immX3AVD 140.0 ± 16.7** 92.2 ± 29.4 100.6 ± 15.9 12.5 ± 7.1** 5.2 immX5AVD 66.6 ± 7.2** 52.8 ± 4.0** 76.8 ± 5.9 9.6 ± 6.5** n.d. = not determined; - A third binding experiment was done as described above using immX3AVD peptide with or without 10 ug/well holotransferrin (holoTf) plus either 10 ug/well LMW-HA or either 1.5 ug or 10 ug HMW-HA/well in the binding step, followed by a buffer wash step. 100 ng/well pure recombinant CD44 protein (Abcam, Waltham, MA) was then added to the indicated wells, incubated for 60 minutes at room temperature and the plate was washed with buffer. Anti-CD44 monoclonal antibody (Abcam, Waltham, MA) was added towells at 1:200, incubated for 60 minutes at room temperature and the plate was then washed and developed by secondary antibody and TMB detection as recommended by the manufacturer. CD44 immunoreactivity was expressed in arbitrary immunoreactivity units (AU), with **p<0.05 versus immx3AVD+1.5 ug HMW-HA control, which was set to=100 AU. Results are shown below:
-
PH Peptide CONTROL 1.5 ug/w HMW-HA 10 ug/w HMW-HA 10 ug/w LMW-HA 7.4 None (buffer) 1.5 ± 15.8** n.d. n.d. n.d. 7.4 immX3AVD 19.6 ± 13.0** 100.0 ± 15.5 101.1 ± 4.9 103.0 ± 19.4 7.4 immX3AVD + 3.1 ± 11.5** 98.3 ± 11.0 107.0 ± 1.9 38.7 ± 4.4** holoTf 5.2 None (buffer) 0.9 ± 21.5** n.d. n.d. n.d. 5.2 immX3AVD 13.2 ± 22.0** 100.0 ± 4.6 105.1 ± 11.4 102.6 ± 17.9 5.2 immX3AVD + 12.0 ± 21.2** 103.3 ± 15.7 94.8 ± 9.5 27.4 ± 6.5** holoTf n.d. = not determined; - Differentiation assays employed the C2C12 myoblastic cell line (ATCC, Manassas, VA) seeded at 2×10e5 cells per well in 96-well plates and cultured at 37 degrees C. in DMEM growth medium plus 10% fetal bovine serum and 1% penicillin/streptomycin. For differentiation, 10% fetal bovine serum was replaced with 2% horse serum. 0.66 uM peptide was then added, and incubation continued for an additional 96 hours. Plates with adherent cells were washed with PBS, lysed with Lytic-M buffer (Sigma Chemical Company, St. Louis, MO) and the lysates were assayed for creatine kinase using a kit purchased from Bioassay Systems (Cat. #ECPK-100, Hayward, CA). Effects were visually confirmed with microscopy tracking myotube formation. Results were expressed as units per milliliter relative to the control immX3AVD peptide, and p values were also calculated and shown relative to control immX3AVD peptide (** p<0.05 versus immX3AVD control; avg±SD).
-
PEPTIDE Creatine Kinase Act. Helper molecule None (buffer) 0.7 ± 2.6** none immX3AVD 100.0 ± 2.2 none immX3AVD 120.6 ± 2.5** Tf immX3AVD 136.7 ± 13.3 Tf + LMW-HA (2 ug/ml) immX3AVD 33.2 ± 3.2 # Tf + HMW-HA (2 ug/ml) immX3AVD 161.5 ± 6.5** L-ornithine (1 mM) immX3AVD 140.3 ± 8.3** D-raffinose (1 mM) immX3AVD 174.2 ± 5.0** GW 501516 (2 uM) immX3AVD 67.4 ± 5.2** GW 3965 (2 uM) immX3AVD 109.4 ± 3.2** ciprofibrate (2 uM) immX3dAdVdD 132.8 ± 5.2** none immX3dSdVdD 155.6 ± 14.1** none immX3K4e + 1 178.4 ± 7.6** none # p < 0.05 vs immX3AVD + Tf; Tf = holotransferrin at 2 ug/ml; L/HMW-HA = low/high-molecular wt hyaluronan;
Another non-myeloid lineage was also tested. Primary human T-cells pre-selected for recognizing GAD65 peptide antigen, and the peptide antigen itself were purchased from Cellero LLC (Memphis, TN). THP1-Dual cells were treated with both GAD65 peptide antigen (1 ug/ml) and immodulin peptide (0.66 uM) using the protocol described in Example 2. After completion of the myeloid cell differentiation step (24 hours), supernatants were collected and 100,000 primary T-cells were added to each well in RPMI-1640 medium (100 uL per well). Plates were incubated for an additional 96 hours and cell extracts were prepared using CellLytic-M reagent (Sigma Chemical Co., St Louis, MO). Supernatants were assayed for CCL22, IL-10 and TGFbeta, and cell extracts assayed for FoxP3, all by ELISA using reagents from R&D Systems, Minneapolis, MN. The results are shown in the table below (**p<0.05 vs immX3AVD, set to=100): -
PEPTIDE GAD65 CCL22 (pg/ml) IL-10 (pg/ml) TGFb (pg/ml) FoxP3 (AU) None None 5.8 ± 1.3** 160 ± 86.1** 15.4 ± 0.4** 23.4 ± 10.1** immX5AVD 1 ug/ml 58.7 ± 2.7** 870 ± 8.2** 52.8 ± 7.4** 14.8 ± 4.3** immX3AVD 1 ug/ml 88.8 ± 13.6 1331 ± 94.3 131.4 ± 41.4 100.0 ± 20.5 immX3dSdVdD 1 ug/ml 77.8 ± 2.0 1534 ± 176.4 87.6 ± 10.7 176.6 ± 8.0** immX3K1dSdVdD 1 ug/ml 554.5 ± 59.3** 7038 ± 168.1** 780.7 ± 51.7** 205.5 ± 8.4**
Yet another non-myeloid lineage was tested. Osteoblast cell line MC3T3E1 was purchased from ATCC (Manassas, VA) and grown in 96-well plates in alpha-MEM medium supplemented with 50 ug/ml ascorbic acid and 5 mM beta-glycerophosphate. Peptides were added and incubation proceeded for 5 days. Cells were washed with PBS buffer and extracts prepared using 100 uL 1X RIPA buffer (Cayman Chemical Company; Ann Arbor, MI) per well. Alkaline phosphatase was measured using 0.37 mg/ml 4-nitrophenyl phosphate in DEA buffer (both reagents purchased from Cayman Chemical Company) by measuring the slope of absorbance at 405 nm using a spectrophotometer. 10 uL of RIPA extract was used for each assay. Separately, protein concentration of extract was measured using a commercial kit. Values were corrected for protein concentration. Results are shown below (**p<0.05 vs immX3AVD=100): -
PEPTIDE (0.66 uM) Compound added Alk. Phos. Activity immX3AVD None 100.0 ± 0.5 immX3AVD 1 mM L-ornithine 159.7 ± 4.4** immX3AVD 1 mM D-raffinose 134.6 ± 4.6** immX3AVD 2 uM Ciprofibrate 127.2 ± 2.7** immX3AVD 2 uM GW 501516 168.7 ± 3.0** immX3AVD 2 uM GW 3965 59.1 ± 4.3** - Similar results were obtained for covalent attachment of small molecules to an immodulin peptide or to a D-tetrapeptide dLys-dAsp-dLys-dPro, with similar efficiencies of coupling to either peptide, thereby demonstrating the generality of the method. Peptides were synthesized according to a common Fmoc/tBu solid phase synthesis strategy well-known in the art. Synthesis may be manual of automated. After the peptide synthesis the resin was divided into batches of 20 umol. Each batch was treated with one of the organic compounds specified in the table shown immediately below. The coupling was carried out using 2 equivalents of the compound, 2.4 equivalents of activator HATU or HCTU, and 4 equivalents of NMM base. The reaction mixture was renewed after 2 hrs reaction time and allowed to react another 4 hrs or overnight. After washing the resin several times with DMF, and subsequently with DCM, the batches were dried. For the cleavage of the peptides from the resin the resins were treated with 1% DTT, 2% water and 3% TIPS in TFA for 3.5 hrs. The cleavage solution was separated from the resin and treated with diethylether/n-pentane (1:1). The resulting precipitate was centrifuged and the pellet washed three times in the same DEE/pentane mixture. The recovered peptide was air dried and stored at −20 degrees C. or further purified by HPLC using a 0-50% acetonitrile gradient, 0.1% trifuoroacetic acid (20 min). The results of the above conjugation experiments show that, both inter-class and intra-class, there is wide variation in conjugation efficiency from compound to compound. It appears that the chance of practical success (>80% correct yield, for instance) for each instantiation of this technology is less than 50% until tested.
-
Class Compound CAS No. MW Yld T4* Yld IM3* fatty acid oleic acid 112-80-1 282.5 44.21% fatty acid eicosapentaenoic acid 10417-94-4 302.5 66.79% fatty acid lignoceric acid 557-59-5 368.6 89.20% fatty acid decanoic acid 1002-62-6 172.2 88.67% 98.0% fatty acid docosahexanoic acid 6217-54-5 368.6 57.77% fatty acid lauric acid 143-07-7 200.3 85.14% 96.7% fatty acid 10-hydroxy-2-decenoic acid 14113-05-4 186.3 44.38% phenolic acid ferulic acid 1135-24-6 194.2 26.58% phenolic acid isoferulic acid 537-73-5 194.2 55.80% 70.2% phenolic acid Aspirin 50-78-2 180.2 56.5% phenolic acid valeroyl salicylate 64206-54-8 222.2 11.76% pentacyclic betulinic acid 472-15-1 456.7 <1% anthraquinone Rhein 478-43-3 284.2 50.95% anthraquinone Diacerein 13939-02-1 368.3 43.2% xanthone 2,7-dichlorodihydro- 4091-99-0 487.3 91.2% proprionic acid (s)-ketoprofen 22161-81-5 254.3 77.86% proprionic acid Ibuprofen 15687-27-1 206.3 93.42% 98.0% carboxylic acid trans-cinnamic acid 140-10-3 148.2 93.12% 81.5% carboxylic acid (s)-(−)-perillic acid 23635-14-5 166.2 27.96% carboxylic acid fenofibric acid 42017-89-0 318.8 85.67% 99.9% indoleacetic acid Indomethacin 53-86-1 357.8 87.5% 85.2%# pentanoic acid valproic acid 1069-66-5 144.2 91.43% 84.9% alkynoic acid 2-hexyl-pentynoic acid 96017-59-3 182.3 85.1% indolylcarboxylic RG-108 48208-26-0 334.3 74.3%@ retinoid all-trans retinoic acid 302-79-4 300.4 13.1% rexinoid Bexarotene 153559-49-0 348.5 97.09% 94.4% *% yield by MS for T4 (tetrapeptide) and imm3 peptide (>80% in bold type); #lost p-chlorophenone group; @indole core oxidized by Arg (protecting gp); - Immodulin peptides have potential untility in the field of cosmetics. HFF-1 human fibroblast cell line was obtained from the American Type Culture Collection (ATCC). Cells were grown in a T-75 flask in DMEM Medium containing 10% fetal bovine serum and penicillin-streptomycin at 37° C. in a humidified, 5% CO2 incubator. Cells (100 ml, 2,000 cells/well) were plated in a 96-well plate and incubated overnight at 37° C. in a humidified, 5% CO2 incubator. Next day, 10 ml/well of compounds were added (quadruplicate wells). After 72 hour incubation with the compound, supernatants were collected for Collagen-1 ELISA assay and cell viability was measured in a luminometer after the addition of 100 mL/well CellTiterGlo reagent (Promega Inc, Madison, WI) as recommended by the manufacturer. Collagen stimulating activity of immodulin peptides in HFF-1 dermal fibroblasts: Peptides were added to cells at 2 uM. Collagen-1A1 (COL1) immunoreactivity was measured in the supernatants of cultured cells by ELISA using a rabbit monoclonal anti-COL1 primary antibody (Abcam, Cambridge, MA). The results of this experiment are shown in the Table below. Control (buffer) value of immunoreactivity was set to 100. The data show that collagen stimulating activity of various immodulin peptides N-modified with small molecules are influenced by the specific amino acid extension sequences and by the N-terminally conjugated carboxylic acids. *p<0.05, **p<0.01 vs “no peptide” control; bex=bexarotene; isf=isoferulic; vlp=valproic; dec=decanoic; cin=cinnamic; rhn=rhein;
-
Peptide Sequence COL1 No peptide 100 imm3 KKGFYKKKQCRPSKGRKRGFCW 101 imm4 RNGNFHPKQCHPALDGQRGKCW 105 imm5 RKGFYKRKQCKPSRGRKRGICW 93 imm3bex (bex)-KKGFYKKKQCRPSKGRKRGFCW 102 imm3isf (isf)-KKGFYKKKQCRPSKGRKRGFCW 131* imm3vlp (vlp)-KKGFYKKKQCRPSKGRKRGFCW 157** imm3dec (dec)-KKGFYKKKQCRPSKGRKRGFCW 114 imm3cin (cin)-KKGFYKKKQCRPSKGRKRGFCW 106 imm3rhn (rhn)-KKGFYKKKQCRPSKGRKRGFCW 68** imm3K9 AFNSYELGSKGFYKKKQCRPSKGRKRGFCW 155** imm3K9.1 AFNSYELGSKKGFYKKKQCRPSKGRKRGFCW 156** imm3K9c AFNSYELGSKGFYKKKQCRPSKGRKRGFCWAVDKY 158** imm3K8 FNSYELGSLKKGFYKKKQCRPSKGRKRGFCW 98 - While preferred embodiments of the present invention have been shown and described herein, it will be apparent to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.
Claims (17)
1. A method for stimulating levels of differentiation markers in myeloid and non-myeloid mammalian cell lineages in vivo or ex vivo, the method comprising:
(i) contacting one or more mammalian cells of a myeloid lineage with a synthetic immodulin peptide about 20 to about 60 amino acids in length and comprising an amino acid sequence corresponding to any one of SEQ ID NOs:1-6; and
(ii) contacting one or more mammalian cells of a non-myeloid lineage with said synthetic immodulin peptide;
(iii) measuring a readout of differentiation for the myeloid mammalian cell lineage wherein said readout is accompanied by a significantly increased average level of at least one marker for myeloid lineage differentiation in the contacted cells of the myeloid lineage and wherein the at least one marker for myeloid lineage differentiation comprises CD169; and
(iv) measuring a readout of differentiation for the non-myeloid mammalian cell lineage wherein said readout is accompanied by a significantly increased average level of at least one marker for non-myeloid lineage differentiation in the contacted cells of the non-myeloid lineage;
wherein cells of said myeloid and non-myeloid lineages following the contacting steps are co-resident in a living tissue.
2. The method according to claim 1 , wherein the at least one marker for myeloid differentiation comprises a marker selected from the group consisting of: CCL22, Clec4A, Clec9a, Clec10a and Clec12a.
3. The method according to claim 1 , wherein the one or more mammalian cells of a non-myeloid lineage are from a neurogenic lineage, the readout is neurogenesis, and the at least one marker for non-myeloid differentiation is selected from the group consisting of: synaptophysin, synaptopodin, vimentin, NMDAR, AChR, and PSD95.
4. The method according to claim 1 , wherein the one or more mammalian cells of a non-myeloid lineage are from a myogenic lineage, the readout is myogenesis, and the at least one marker for non-myeloid differentiation is selected from the group consisting of: creatine kinase, myogenin, MYF-5 and actinin-2.
5. The method according to claim 1 , wherein the one or more mammalian cells of a non-myeloid lineage are from a osteogenic lineage, the readout is osteogenesis, and the at least one marker for non-myeloid differentiation is selected from the group consisting of alkaline phosphatase, calcified deposits, osteocalcin and BMP-2.
6. The method according to claim 1 , wherein the one or more mammalian cells of a non-myeloid lineage are from a fibroblastic lineage, the readout is dermal regeneration, and the at least one marker for non-myeloid differentiation is Col1A1.
7. The method according to claim 1 , wherein the one or more mammalian cells of a non-myeloid lineage are from a lymphocytic lineage, the readout is regulatory lymphocyte proliferation, and the at least one marker for non-myeloid differentiation is selected from the group consisting of: FoxP3 and IL-10.
8. The method according to claim 1 , wherein the synthetic immodulin peptide is covalently linked to at least one small non-amino acid molecule of molecular mass less than one thousand daltons.
9. The method according to claim 8 , wherein the small non-amino-acid molecule is selected from a group consisting of: PF-06409577, AICAR, D942, PT1, EX-229, GIT27, GW501516, GW3965, GW9578, RB394, MBX-8025, GW7647, ZLY032, GW590735, GW0742, Amorfrutin B, BMS195614, GW4064, BMS453, FTY720, artesunate, sobetirone, cilofexor, decanoic acid, eicosapentaenoic acid, docosahexanoic acid, lignoceric acid, TTNPB, adapalene, bexarotene, transcinnamic acid, fenofibric acid, ciprofibrate, chlorfibric acid, gemfibrozil, elafibrinor, pioglitazone, roziglitazone, valproic acid, 2-hexyl-4-pentynoic acid, and ibuprofen.
10. The method according to claim 8 , wherein the synthetic immodulin peptide is co-administered with a helper molecule selected from a group consisting of: ornithine, leucine, raffinose, trehalose, resveratrol, polydatin, ursolic acid, lactate, bile salt, metal, cyclodextrin and cyclic dinucleotide.
11. The method according to claim 8 , wherein the amino acid sequence of said synthetic immodulin peptide further comprises any of SEQ ID NOs: 7-14.
12. The method according to claim 8 , wherein the synthetic peptide is provided in a complex with non-covalently bound, purified holotransferrin at about 0.1 to about 10 molar equivalents.
13. The method according to claim 12 , wherein said synthetic peptide-holotransferrin complex further comprises about 0.01 to about 100 molar equivalents of purified high-molecular weight hyaluronan, wherein binding of said synthetic immodulin peptide-holotransferrin complex to high-molecular weight hyaluronan is significantly stronger at pH 5.2 than at pH 7.4.
14. The method according to claim 12 , wherein said synthetic peptide-holotransferrin complex further comprises about 0.01 to about 100 molar equivalents of purified high-molecular weight hyaluronan, wherein binding of said synthetic immodulin peptide-holotransferrin complex to high-molecular weight hyaluronan is significantly stronger than binding of said synthetic immodulin peptide-holotransferrin complex to low-molecular weight hyaluronan at pH 7.4.
15. (canceled)
16. A composition comprising a pH-sensitive non-covalent complex of:
(i) a synthetic immodulin peptide about 20 to about 60 amino acids in length;
(ii) about 0.1 to about 10 molar equivalents of purified holotransferrin; and
(iii) about 0.01 to about 100 molar equivalents of purified high-molecular weight hyaluronan, wherein binding of said high-molecular weight hyaluronan within said pH-sensitive non-covalent complex is significantly stronger at pH than at pH 7.4.
17. A composition comprising a size-sensitive non-covalent complex of:
(i) a synthetic immodulin peptide about 20 to about 60 amino acids in length;
(ii) about 0.1 to about 10 molar equivalents of purified holotransferrin; and
(iii) about 0.01 to about 100 molar equivalents of purified high-molecular weight hyaluronan, wherein binding of said high-molecular weight hyaluronan within said size-sensitive non-covalent complex is significantly stronger than binding to low-molecular weight hyaluronan at pH 7.4.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2021/046814 WO2022191868A1 (en) | 2020-03-26 | 2021-08-20 | Modulation of mammalian cell lineage by synthetic immodulins |
PCT/US2022/018449 WO2022192042A2 (en) | 2021-03-09 | 2022-03-02 | Regeneration of mammalian tissues using synthetic immodulins |
Publications (1)
Publication Number | Publication Date |
---|---|
US20240034761A1 true US20240034761A1 (en) | 2024-02-01 |
Family
ID=83228528
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US18/264,233 Pending US20240034761A1 (en) | 2021-08-20 | 2022-03-02 | Regeneration of mammalian tissues using synthetic immodulins |
Country Status (4)
Country | Link |
---|---|
US (1) | US20240034761A1 (en) |
CA (2) | CA3207815A1 (en) |
GB (1) | GB2620502A (en) |
WO (2) | WO2022192042A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3207815A1 (en) * | 2021-03-09 | 2022-09-15 | Desmond Mascarenhas | Modulation of mammalian cell lineage by synthetic immodulins |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU6515499A (en) * | 1998-10-16 | 2000-05-08 | Musc Foundation For Research Development | Fragments of insulin-like growth factor binding protein and insulin-like growth factor, and uses thereof |
AU2005243741B2 (en) * | 2001-09-18 | 2010-01-28 | Bioexpertise Llc | Methods for delivering MBD peptide- linked agent into cells under conditions of cellular stress |
US6914049B2 (en) * | 2001-09-18 | 2005-07-05 | Bioexpertise, Llc | IGF-binding protein-derived peptide or small molecule |
JP3968383B2 (en) * | 2004-09-01 | 2007-08-29 | 株式会社日本メディカル総研 | Novel classification method of blood cells and tailor-made treatment and prevention using it |
US7662624B2 (en) * | 2005-11-09 | 2010-02-16 | Ontherix, Inc. | Metal-binding therapeutic peptides |
ES2418434T3 (en) * | 2006-08-16 | 2013-08-13 | National Research Council Of Canada | Inhibition of angiogenesis, tumorigenesis and cathepsin activity using an insulin-like growth factor binding protein |
US8536135B2 (en) * | 2008-03-19 | 2013-09-17 | Ontherix, Inc. | Adaptive biochemical signatures |
WO2013097152A1 (en) * | 2011-12-29 | 2013-07-04 | 财团法人工业技术研究院 | Ph-sensitive hyaluronic acid derivative and use thereof |
KR101482708B1 (en) * | 2012-10-09 | 2015-01-14 | 성균관대학교산학협력단 | Novel use of C-terminal domain of IGFBP-5 comprising heparin-binding domain as an angiogenesis inhibitor |
EP3055298B1 (en) * | 2013-10-11 | 2020-04-29 | Sutro Biopharma, Inc. | Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use |
WO2016049641A1 (en) * | 2014-09-28 | 2016-03-31 | The Regents Of The University Of California | Modulation of stimulatory and non-stimulatory myeloid cells |
US10960045B2 (en) * | 2015-10-14 | 2021-03-30 | Constant Therapeutics Llc | Methods and compositions for the treatment of epidermolysis bullosa |
CN105944108B (en) * | 2016-04-22 | 2021-02-02 | 烟台大学 | PH sensitivity modifier of liposome containing menthone ketal and paclitaxel-curcumin compound liposome preparation |
AU2020437795A1 (en) * | 2020-03-26 | 2022-08-11 | Desmond Mascarenhas | Immodulator peptides covalently modified with small molecules |
CA3207815A1 (en) * | 2021-03-09 | 2022-09-15 | Desmond Mascarenhas | Modulation of mammalian cell lineage by synthetic immodulins |
-
2021
- 2021-08-20 CA CA3207815A patent/CA3207815A1/en active Pending
- 2021-08-20 GB GB2312911.7A patent/GB2620502A/en active Pending
-
2022
- 2022-03-02 US US18/264,233 patent/US20240034761A1/en active Pending
- 2022-03-02 WO PCT/US2022/018449 patent/WO2022192042A2/en active Application Filing
- 2022-03-02 CA CA3209547A patent/CA3209547A1/en active Pending
-
2023
- 2023-02-26 WO PCT/US2023/013908 patent/WO2023167813A2/en active Search and Examination
Also Published As
Publication number | Publication date |
---|---|
WO2023167813A3 (en) | 2023-10-12 |
WO2023167813A2 (en) | 2023-09-07 |
CA3209547A1 (en) | 2022-09-15 |
WO2023167813A4 (en) | 2023-11-09 |
CA3207815A1 (en) | 2022-09-15 |
GB2620502A (en) | 2024-01-10 |
WO2022192042A3 (en) | 2022-12-22 |
GB202312911D0 (en) | 2023-10-04 |
WO2022192042A2 (en) | 2022-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7399831B2 (en) | Targeted delivery of biological factors using self-assembling peptide nanofibers | |
AU722700B2 (en) | Lipophilic peptides for macromolecule delivery | |
CA2539288C (en) | Thyroid hormone analogs and methods of use | |
EP1833504A2 (en) | Sustained delivery of pdgf using self-assembling peptide nanofibers | |
EP0871440A4 (en) | Treatment of negative and cognitive symptoms of schizophrenia with glycine uptake antagonists | |
US9867869B2 (en) | Insulin derivatives for diabetes treatment | |
US20180021323A1 (en) | Flip - a selective molecular target of senescent cells | |
JP2010503710A5 (en) | ||
WO2022191868A1 (en) | Modulation of mammalian cell lineage by synthetic immodulins | |
JP2018507865A (en) | Targeted transplantation of mitochondria into hepatocytes | |
US20240034761A1 (en) | Regeneration of mammalian tissues using synthetic immodulins | |
US20160122411A1 (en) | Cartilage-binding fusion proteins | |
CN108712913B (en) | Tri-part modulators of endosomal G protein-coupled receptors | |
Zhang et al. | Tetramethylpyrazine alleviates diabetes-induced high platelet response and endothelial adhesion via inhibiting NLRP3 inflammasome activation | |
US20110020471A1 (en) | Erythrocyte atp-release modulators | |
US20210060122A1 (en) | Method For Treating Cerebral Stroke | |
US20190389903A1 (en) | Insulin a-chain derived peptide fragment and pharmaceutical composition for preventing or treating diabetes or diabetic wounds, containing the same | |
Xu et al. | Targeted transplantation of engineered mitochondrial compound promotes functional recovery after spinal cord injury by enhancing macrophage phagocytosis | |
WO2005072270A2 (en) | Methods and compositons for treating cancer | |
US11191806B2 (en) | Polymyxin-based pharmaceutical composition for treating infectious diseases | |
US10738294B2 (en) | Tissue factor (TF)—targeted nanotherapy | |
Mascarenhas | Immodulin peptides influence musculoskeletal homeostasis by linking extracellular cues to macrophage and myoblast nuclear receptors | |
BR102015031283A2 (en) | BIOCONJUGATE OF HUMAN AMILINE OR AGILAGING ANALOGUE, COMPOSITION, METHODS FOR PREPARATION OF A COMPOSITION, FOR THE TREATMENT OF AN OCCONDITION DISEASE, AND TO STABILIZE AN AMYLIME MIMETIC COMPOUND, AND | |
Ravichandran et al. | Syncytin-1 Expression is Increased in Skeletal Muscle of Humans with Obesity and is Inversely Correlated to Muscle Protein Synthesis | |
CA2805552C (en) | Polymeric conjugates of anti-angiogenesis agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |